INVACARE (IVCRQ) 10-Q 5 May 21 2021 Q1 Quarterly report Financial data

DEI Document

DEI Document - shares	3 Months Ended
	Mar. 31, 2021	May 03, 2021
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2021
Document Transition Report	false
Entity File Number	001-15103
Entity Registrant Name	INVACARE CORPORATION
Entity Incorporation, State or Country Code	OH
Entity Tax Identification Number	95-2680965
Entity Address, Address Line One	One Invacare Way,
Entity Address, City or Town	Elyria,
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	44035
City Area Code	440
Local Phone Number	329-6000
Title of 12(b) Security	Common Shares, without par value
Trading Symbol	IVC
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Central Index Key	0000742112
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false
Common Shares [Member]
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		34,951,521
Class B Common Shares [Member]
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		3,667

Condensed Consolidated Statemen

Condensed Consolidated Statement of Comprehensive Income (Loss) - USD ($) shares in Thousands		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Statement of Comprehensive Income [Abstract]
Net Sales		$ 196,202,000	$ 218,440,000
Cost of products sold		141,564,000	155,452,000
Gross Profit		54,638,000	62,988,000
Selling, general and administrative expenses		58,821,000	61,738,000
Gain on sale of business		0	9,590,000
Charges related to restructuring activities		1,552,000	1,392,000
Operating Income (Loss)		(5,735,000)	9,448,000
Loss on debt extinguishment including debt finance charges and fees		709,000	0
Interest expense		5,731,000	6,676,000
Interest Income, Other		1,000	60,000
Earnings (Loss) Before Income Taxes		(12,174,000)	2,832,000
Income tax provision		1,870,000	2,100,000
Net Income (Loss)		$ (14,044,000)	$ 732,000
Dividends Declared per Common Share		$ 0	$ 0.0125
Net Income (Loss) per Share—Basic
Net Income (Loss) per Share—Basic		$ (0.41)	$ 0.02
Weighted Average Shares Outstanding—Basic		34,495	33,784
Net Income (Loss) per Share—Assuming Dilution
Net Income (Loss) per Share—Assuming Dilution	[1]	$ (0.41)	$ 0.02
Weighted Average Shares Outstanding—Assuming Dilution		35,210	33,853
Other comprehensive income (loss):
Foreign currency translation adjustments		$ 5,677,000	$ (4,194,000)
Defined Benefit Plans:
Amortization of prior service costs and unrecognized losses		349,000	(169,000)
Deferred tax adjustment resulting from defined benefit plan activity		(58,000)	18,000
Valuation reserve associated with defined benefit plan activity		58,000	(18,000)
Current period loss on cash flow hedges		(875,000)	(142,000)
Deferred tax benefit (provision) related to gain on cash flow hedges		83,000	0
Other Comprehensive Income (Loss)		5,234,000	(4,505,000)
Comprehensive Loss		$ (8,810,000)	$ (3,773,000)
Net Sales, as a Percent of Net Sales		100.00%	100.00%
Cost of Products Sold, as a Percent of Net Sales		72.20%	71.20%
Gross Profit, as a Percent of Net Sales		27.80%	28.80%
Selling, general and administrative expenses, as a Percent of Net Sales		30.00%	28.30%
Gain on sale of business, as a Percent of Net Sales		0.00%	(4.40%)
Charges related to restructuring activities, as a Percent of Net Sales		0.80%	0.60%
Operating Gain (Loss), as a Percent of Net Sales		(2.90%)	4.30%
Interest expense, as a Percent of Net Sales		2.90%	3.10%
Interest income, as a Percent of Net Sales		0.00%	0.00%
Gain (loss) Before Income Taxes, as a Percent of Net Sales		(6.20%)	1.30%
Income Tax Provision, as a Percent of Net Sales		1.00%	1.00%
Net Gain (Loss), as a percent of Net Sales		(7.20%)	0.30%
Net loss (gain) on debt extinguishment, as a Percent of Net Sales [Line Items]		0.40%
[1]	Net income (loss) per common share assuming dilution calculated utilizing weighted average shares outstanding-basic for the periods in which there was a net loss.

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current Assets
Cash and cash equivalents	$ 86,052	$ 105,298
Trade receivables, net	99,773	108,588
Installment receivables, net	239	379
Inventories, net	132,394	115,484
Other current assets	35,483	44,717
Total Current Assets	353,941	374,466
Other Assets	5,643	5,925
Intangibles, net	28,066	27,763
Property and Equipment, net	57,793	56,243
Finance Lease, Right-of-Use Asset	69,096	64,031
Operating Lease, Right-of-Use Asset	14,053	15,092
Goodwill	407,726	402,461
Total Assets	936,318	945,981
Current Liabilities
Accounts payable	93,111	85,424
Accrued expenses	112,278	126,273
Current taxes payable	2,470	3,359
Current portion of long-term debt	4,840	5,612
Current portion of finance lease obligations	3,584	3,405
Current portion of operating lease obligations	5,610	6,313
Total Current Liabilities	221,893	230,386
Long-Term Debt	283,750	239,441
Finance Lease Long-Term Obligations	68,346	63,137
Operating Leases Long-Term Obligations	8,356	8,697
Other Long-Term Obligations	71,272	70,474
Shareholders’ Equity
Preferred Shares (Authorized 300 shares; none outstanding)	0	0
Additional paid-in-capital	273,982	326,088
Retained earnings	54,164	58,538
Accumulated other comprehensive income	50,670	45,436
Treasury Shares (4,184 and 4,184 shares at March 31, 2021 and December 31, 2020, respectively)	(106,034)	(106,034)
Total Shareholders’ Equity	282,701	333,846
Total Liabilities and Shareholders’ Equity	936,318	945,981
Common Shares [Member]
Shareholders’ Equity
Common Shares	9,917	9,816
Class B Common Shares [Member]
Shareholders’ Equity
Common Shares	2	2
Total Shareholders’ Equity	$ 2	$ 2

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - shares shares in Thousands	Mar. 31, 2021	Dec. 31, 2020
Preferred Stock, Shares Authorized	300	300
Preferred Stock, Shares Outstanding	0	0
Treasury Stock, Shares	4,184	4,184
Common Shares [Member]
Common Stock, Shares Authorized	150,000	150,000
Common Stock, Shares, Issued	39,007	38,613
Class B Common Shares [Member]
Common Stock, Shares Authorized	12,000	12,000
Common Stock, Shares, Issued	4	4

Condensed Consolidated Statem_2

Condensed Consolidated Statement Of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Convertible debt discount amortization and accretion	$ 870,000	$ 2,732,000
Purchases of capped calls	(18,787,000)	0
Operating Activities
Net income (loss)	(14,044,000)	732,000
Adjustments to reconcile net income (loss) to net cash used by operating activities:
Gain on sale of business	0	9,590,000
Depreciation and amortization	4,079,000	3,407,000
Amortization of operating lease right of use assets	1,634,000	1,937,000
Provision for losses on trade and installment receivables	45,000	(71,000)
Benefit for deferred income taxes	672,000	240,000
Provision (benefit) for other deferred liabilities	(72,000)	469,000
Provision for equity compensation	1,580,000	1,200,000
Loss (gain) on disposals of property and equipment	0	1,000
Loss on debt extinguishment including debt finance charges and fees	709,000	0
Convertible debt discount amortization and accretion	870,000	2,732,000
Amortization of debt fees	418,000	475,000
Changes in operating assets and liabilities:
Trade receivables	9,768,000	1,627,000
Installment sales contracts, net	228,000	26,000
Inventories, net	(16,018,000)	(2,930,000)
Other current assets	9,761,000	(10,934,000)
Accounts payable	6,197,000	7,950,000
Accrued expenses	(20,214,000)	(5,787,000)
Other long-term liabilities	627,000	(1,323,000)
Net Cash Provided by (Used in) Operating Activities	(13,760,000)	(9,839,000)
Investing Activities
Purchases of property and equipment	(4,118,000)	(2,121,000)
Proceeds from sale of property and equipment	23,000	4,000
Proceeds from sale of business	0	14,563,000
Change in other long-term assets	2,000	(135,000)
Other	0	2,113,000
Net Cash Provided (Used) by Investing Activities	(4,093,000)	10,198,000
Financing Activities
Proceeds from revolving lines of credit and long-term borrowings	125,000,000	21,600,000
Repurchases of convertible debt, payments on revolving lines of credit and finance leases	(104,079,000)	(266,000)
Payment of financing costs	(4,608,000)	0
Payment of dividends	0	(414,000)
Purchases of capped calls	(18,787,000)	0
Purchases of treasury shares	0	(773,000)
Net Cash Provided (Used) by Financing Activities	(2,474,000)	20,147,000
Effect of exchange rate changes on cash	1,081,000	(1,637,000)
Cash, Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	(19,246,000)	18,869,000
Cash and cash equivalents at beginning of year	105,298,000	80,063,000
Cash and cash equivalents at end of period	$ 86,052,000	$ 98,932,000

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Shareholders' Equity Statement - USD ($)	Total	Class B Common Shares [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]
Total Shareholders’ Equity at Dec. 31, 2019	$ 308,516,000	$ 2,000	$ 9,588,000	$ 312,650,000	$ 87,475,000	$ 3,128,000	$ (104,327,000)
Allocated Share-based Compensation Expense	(380,000)		90,000	304,000			(774,000)
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	806,000		137,000	669,000			0
Net Loss	732,000				732,000
Foreign currency translation adjustments	(4,194,000)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	(4,194,000)
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax	(142,000)					(142,000)
Amortization of prior service costs and unrecognized losses	(169,000)
Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, after Tax	(169,000)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	(3,773,000)
Payments of Ordinary Dividends, Common Stock	(414,000)
Dividends, Common Stock, Cash	(414,000)
Purchases of capped calls	0
Total Shareholders’ Equity at Mar. 31, 2020	304,512,000	2,000	9,815,000	313,623,000	87,550,000	(1,377,000)	(105,101,000)
Adoption of Credit Loss Standard	(243,000)				(243,000)
Total Shareholders’ Equity at Dec. 31, 2020	333,846,000	2,000	9,816,000	326,088,000	58,538,000	45,436,000	(106,034,000)
Allocated Share-based Compensation Expense	668,000			668,000
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	912,000		101,000	811,000			0
Net Loss	(14,044,000)				(14,044,000)
Foreign currency translation adjustments	5,677,000
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	5,677,000
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax	(792,000)					(792,000)
Amortization of prior service costs and unrecognized losses	349,000
Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, after Tax	349,000
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	(8,810,000)
Payments of Ordinary Dividends, Common Stock	0
Adoption of ASU 2020-06	(25,128,000)			(34,798,000)	9,670,000
Purchases of capped calls	(18,787,000)
Total Shareholders’ Equity at Mar. 31, 2021	$ 282,701,000	$ 2,000	$ 9,917,000	$ 273,982,000	$ 54,164,000	$ 50,670,000	$ (106,034,000)

Accounting Policies

Accounting Policies	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Accounting Policies	Accounting Policies Principles of Consolidation: The condensed consolidated financial statements include the accounts of the company and its wholly owned subsidiaries and include all adjustments, which were of a normal recurring nature, necessary to present fairly the financial position of the company as of March 31, 2021 and the results of its operations and changes in its cash flow for the three months ended March 31, 2021 and 2020, respectively. Certain foreign subsidiaries, represented by the European segment, are consolidated using a February 28 quarter end to meet filing deadlines. No material subsequent events have occurred related to the European segment, which would require disclosure or adjustment to the company's financial statements. All significant intercompany transactions are eliminated. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the full year. Use of Estimates: The condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States, which require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from these estimates. Recent Accounting Pronouncements (Already Adopted): In August 2020, the FASB issued ASU 2020-06 "Debt with Conversion and Other Options" (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity's Own Equity (Subtopic 815-40)", which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. ASU 2020-06 removes from U.S. GAAP the separation models for (1) convertible debt with a cash conversion feature (CCF) and (2) convertible instrument with a beneficial conversion feature (BCF). As a result, after adopting the ASU’s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC 815 or (2) a convertible debt instrument was issued at a substantial premium. The guidance may be early adopted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The company adopted ASU 2020-06 effective January 1, 2021, using the modified retrospective method, which resulted in the removal of convertible debt discounts of $25,218,000, adjustment of $34,798,000 to additional paid-in-capital and $9,670,000 adjustment to retained earnings. Convertible debt discounts prior to adoption of ASU 2020-06 were amortized over the convertible debt term through interest expense. Subsequent to adoption, convertible debt discounts are not applicable when accounting for debt as a single unit of account. Interest expense for the three months ended March 31, 2020 related to debt discount amortization (which was not recognized in the first quarter of 2021 due to adoption) was $2,732,000 or $0.08 per basic and diluted share. There was no impact of adoption on performance metrics used for short-term or long-term incentive compensation. Accretion specific to the Series II 2024 Notes was unaffected by adoption. Due to the valuation allowance, there was no net impact to income taxes for the adoption. Subsequent to adoption weighted average shares when calculating diluted earnings per share requires the application of the if-converted method for all convertible instruments. Recent Accounting Pronouncements (Not Yet Adopted):

Divested Businesses (Notes)

Divested Businesses (Notes)	3 Months Ended
	Mar. 31, 2021
Divested Businesses [Abstract]
Divested Businesses	Divested Businesses On March 7, 2020, the company, completed the sale (the “Transaction”) of its subsidiary, Dynamic Controls, a New Zealand incorporated unlimited company (“Dynamic Controls”), to Allied Motion Christchurch Limited, a New Zealand limited company (the “Purchaser”), pursuant to a Securities Purchase Agreement among the company, Invacare Holdings New Zealand, a New Zealand incorporated unlimited company, and the Purchaser, dated March 6, 2020 (the “Purchase Agreement”). Dynamic Controls was a producer of electronic control systems for powered medical mobility devices, including systems incorporating the LiNX™ technology platform. Dynamic Controls was a component of the All Other Segment. Dynamic Controls was a supplier of power mobility products and respiratory components to the company as well as supplying power mobility products to external customers. Sales in 2020 through the date of disposition were $5,331,000, including intercompany sales of $2,532,000, compared to sales for the full year of 2019 of $30,261,000, including intercompany sales of $13,087,000. Income before income taxes was approximately $445,000 in 2020, through the date of disposition, compared to $853,000 in 2019, inclusive of intercompany profits on sales to the company. The transaction was the result of considering options for the products sold by Dynamic Controls which resulted in selling the business to a third-party which can provide access to further technological innovations to further differentiate the company’s power mobility products. The gross proceeds from the Transaction were $14,563,000, net of taxes and expenses. The company realized a pre-tax gain of $9,790,000 with a remaining accrued expenses balance of $240,000 as of March 31, 2021. The Purchase Agreement contains customary indemnification obligations of each party with respect to breaches of their respective representations, warranties and covenants, and certain other specified matters, which are subject to certain exceptions, terms and limitations described further in the Purchase Agreement. At the closing of the Transaction, the parties entered into a supply agreement pursuant to which Dynamic Controls will supply certain electronic components as required by the company for the five-year period following the Transaction, including ongoing supply and support of the LiNX™ electronic control system with informatics technology, continued contract manufacturing of certain electronic components for the company’s respiratory products and continued infrastructure and applications support for the informatics solution for the company’s respiratory products. The estimated continued inflows and outflows following the disposal with the Purchaser are not expected to be material to the company. The assets and liabilities of Dynamic Controls as of March 7, 2020 consisted of the following (in thousands): March 7, 2020 Trade receivables, net $ 4,129 Inventories, net 3,082 Other assets 855 Property and equipment, net 600 Operating lease assets, net 2,127 Total assets $ 10,793 Accounts payable $ 4,692 Accrued expenses 2,473 Current taxes payable 41 Current portion of operating lease obligations 366 Long-term obligations 1,019 Total liabilities $ 8,591 Trade receivables as of March 7, 2020 includes receivables previously classified as intercompany related to product sold by Dynamic Controls to other Invacare entities.

Receivables

Receivables	3 Months Ended
	Mar. 31, 2021
Receivables [Abstract]
Receivables	Receivables Receivables consist of the following (in thousands): March 31, 2021 December 31, 2020 Accounts receivable, gross $ 118,278 $ 131,055 Customer rebate reserve (8,914) (10,730) Cash discount reserves (4,995) (7,320) Allowance for doubtful accounts (4,172) (4,031) Other, principally returns and allowances reserves (424) (386) Accounts receivable, net $ 99,773 $ 108,588 Reserves for customer rebates and cash discounts are recorded as a reduction in revenue and netted against gross accounts receivable. Customer rebates in excess of a given customer's accounts receivable balance are classified in Accrued Expenses. Customer rebates and cash discounts are estimated based on the most likely amount principle as well as historical experience and anticipated performance. In addition, customers have the right to return product within the company’s normal terms policy, and as such, the company estimates the expected returns based on an analysis of historical experience and adjusts revenue accordingly. Accounts receivable are reduced by an allowance for amounts that may become uncollectible in the future. Substantially all the company’s receivables are due from health care, medical equipment providers and long-term care facilities predominantly located throughout the United States, Australia, Canada, New Zealand and Europe. A significant portion of products sold to providers, both foreign and domestic, are ultimately funded through government reimbursement programs such as Medicare and Medicaid in the U.S. As a consequence, changes in these programs can have an adverse impact on dealer liquidity and profitability. The company's approach is to separate its receivables into good-standing and collection receivables. Good-standing receivables are assigned to risk pools of high, medium and low. The risk pools are driven by the specifics associated with the geography of origination. Expected loss percentages are calculated and assigned to each risk pool, driven primarily by historical experience. The historical loss percentages are calculated for each risk pool and then judgmentally revised to consider current risk factors as well as consideration of the impact of forecasted events, as applicable. The expected loss percentages are then applied to receivables balances each period to determine the allowance for doubtful accounts. In North America, excluding Canada, good-standing receivables are assigned to the low risk pool and assigned an expected loss percentage of 1.0% as these receivables are deemed to share the same risk profile and collections efforts are the same. Installment receivables in North America are characterized as collection receivables and thus reserves based on specific analysis of each customer. In Canada, good-standing receivables are deemed low risk and assigned a loss percentage of 0.2%. In Europe, expected losses are determined by each location in each region. Most locations have a majority of their receivables assigned to the low risk pool, which has an average expected loss percentage of 0.4%. About half of the locations have a portion of their receivables assigned as medium risk with an average expected loss percentage of 1.5%. Only a few locations have any receivables characterized as high risk and the average credit loss percentage for those locations is 2.5%. Collection risk is generally low as payment terms in certain key markets, such as Germany, are immediate and in many locations the ultimate customer is the government. In the Asia Pacific region, receivables are characterized as low risk, which have an average expected loss percentage of 0.3%. Historical losses are low in this region where the use of credit insurance is often customary. The movement in the trade receivables allowance for doubtful accounts was as follows (in thousands): Three Months Ended Balance as of beginning of period $ 4,031 Current period provision 131 Recoveries (direct write-offs), net 10 Balance as of end of period $ 4,172 The company did not make any material changes to the assignment of receivables to the different risk pools or to the expected loss reserves in the quarter. The company is monitoring the impacts of the COVID-19 pandemic and the possibility for an impact on collections, but to date this has not materially impacted 2021. For collections receivables, the estimated allowance for uncollectible amounts is based primarily on management’s evaluation of the financial condition of each customer. In addition, as a result of the company's financing arrangement with DLL, a third-party financing company which the company has worked with since 2000, management monitors the collection status of these contracts in accordance with the company’s limited recourse obligations and provides amounts necessary for estimated losses in the allowance for doubtful accounts and establishes reserves for specific customers as needed. The company writes off uncollectible trade accounts receivable after such receivables are moved to collection status and legal remedies are exhausted. See Concentration of Credit Risk in the Notes to the Condensed Consolidated Financial Statements for a description of the financing arrangement. Long-term installment receivables are included in “Other Assets” on the condensed consolidated balance sheet. The company has recorded a contingent liability in the amount of $407,000 related to the contingent aspect of the company's guarantee associated with its arrangement with DLL. The contingent liability is recorded applying the same expected loss model used for the trade and installment receivables recorded on the company's books. Specifically, historical loss history is used to determine the expected loss percentage, which is then adjusted judgmentally to consider other factors, as needed. The company’s U.S. customers electing to finance their purchases can do so using DLL. The installment receivables recorded on the books of the company represent a single portfolio segment of finance receivables to the independent provider channel and long-term care customers. The portfolio segment is comprised of two classes of receivables distinguished by geography and credit quality. The U.S. installment receivables are the first class and represent installment receivables repurchased from DLL because the customers were in default. Default with DLL is defined as a customer being delinquent by three payments. The estimated allowance for uncollectible amounts and evaluation for both classes of installment receivables is based on the company’s quarterly review of the financial condition of each individual customer with the allowance for doubtful accounts adjusted accordingly. Installments are individually and not collectively reviewed. The company assesses the bad debt reserve levels based upon the status of the customer’s adherence to a legally negotiated payment schedule and the company’s ability to enforce judgments, liens, etc. For purposes of granting or extending credit, the company utilizes a scoring model to generate a composite score that considers each customer’s consumer credit score and/or D&B credit rating, payment history, security collateral and time in business. Additional analysis is performed for most customers desiring credit greater than $250,000, which generally includes a detailed review of the customer’s financial statements as well as consideration of other factors such as exposure to changing reimbursement laws. Interest income is recognized on installment receivables based on the terms of the installment agreements. Installment accounts are monitored and if a customer defaults on payments and is moved to collection, interest income is no longer recognized. Subsequent payments received once an account is put on non-accrual status are generally first applied to the principal balance and then to the interest. Accruing of interest on collection accounts would only be restarted if the account became current again. All installment accounts are accounted for using the same methodology regardless of the duration of the installment agreements. When an account is placed in collection status, the company goes through a legal process for pursuing collection of outstanding amounts, the length of which typically approximates eighteen months. Any write-offs are made after the legal process has been completed. Installment receivables consist of the following (in thousands): March 31, 2021 December 31, 2020 Current Long- Total Current Long- Total Installment receivables $ 455 $ 1,057 $ 1,512 $ 704 $ 1,105 $ 1,809 Allowance for doubtful accounts (216) (151) (367) (325) (162) (487) Installment receivables, net $ 239 $ 906 $ 1,145 $ 379 $ 943 $ 1,322 No installment receivables were purchased from DLL during the three months ended March 31, 2021. No sales of installment receivables were made by the company during the quarter. The movement in the installment receivables allowance for doubtful accounts was as follows (in thousands): Three Months Ended Year Ended December 31, 2020 Balance as of beginning of period $ 487 $ 1,514 Current period provision (benefit) (86) 66 Direct write-offs charged against the allowance (34) (1,093) Balance as of end of period $ 367 $ 487 Installment receivables by class as of March 31, 2021 consist of the following (in thousands): Total Unpaid Related Interest U.S. Impaired installment receivables with a related allowance recorded $ 486 $ 486 $ 367 $ — Asia Pacific Non-Impaired installment receivables with no related allowance recorded 1,026 1,026 — — Total Non-Impaired installment receivables with no related allowance recorded 1,026 1,026 — — Impaired installment receivables with a related allowance recorded 486 486 367 — Total installment receivables $ 1,512 $ 1,512 $ 367 $ — Installment receivables by class as of December 31, 2020 consist of the following (in thousands): Total Unpaid Related Interest U.S. Impaired installment receivables with a related allowance recorded $ 615 $ 615 $ 487 $ — Asia Pacific Non-impaired installment receivables with no related allowance recorded 1,194 1,194 — — Canada Non-impaired installment receivables with no related allowance recorded — — — 29 Total Non-impaired installment receivables with no related allowance recorded 1,194 1,194 — 29 Impaired installment receivables with a related allowance recorded 615 615 487 — Total installment receivables $ 1,809 $ 1,809 $ 487 $ 29 Installment receivables with a related allowance recorded as noted in the table above represent those installment receivables on a non-accrual basis. As of March 31, 2021, the company had no U.S. installment receivables past due of 90 days or more for which the company is still accruing interest. Individually, all U.S. installment receivables are assigned a specific allowance for doubtful accounts based on management’s review when the company does not expect to receive both the contractual principal and interest payments as specified in the loan agreement. The aging of the company’s installment receivables was as follows (in thousands): March 31, 2021 December 31, 2020 Total U.S. Asia Pacific Total U.S. Asia Pacific Current $ 1,026 $ — $ 1,026 $ 1,194 $ — $ 1,194 0-30 days past due — — — — — — 31-60 days past due — — — — — — 61-90 days past due — — — — — — 90+ days past due 486 486 — 615 615 — $ 1,512 $ 486 $ 1,026 $ 1,809 $ 615 $ 1,194

Inventories

Inventories	3 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Inventories	Inventories, Net Inventories consist of the following (in thousands): March 31, 2021 December 31, 2020 Finished goods $ 60,574 $ 55,264 Raw materials 57,855 51,174 Work in process 13,965 9,046 Inventories, net $ 132,394 $ 115,484

Other Current Assets

Other Current Assets	3 Months Ended
	Mar. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Current Assets	Other Current Assets Other current assets consist of the following (in thousands): March 31, 2021 December 31, 2020 Tax receivables principally value added taxes $ 17,697 $ 22,500 Receivable due from information technology provider 3,020 2,995 Prepaid insurance 2,746 3,963 Prepaid inventory 2,106 2,700 Recoverable income taxes 816 2,182 Derivatives (foreign currency forward exchange contracts) 723 1,321 Service contracts 573 633 Deferred financing fees 342 208 Prepaid and other current assets 7,460 8,215 Other Current Assets $ 35,483 $ 44,717

Other Long-Term Assets

Other Long-Term Assets	3 Months Ended
	Mar. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Long-Term Assets	Other Long-Term Assets Other long-term assets consist of the following (in thousands): March 31, 2021 December 31, 2020 Cash surrender value of life insurance policies $ 2,325 $ 2,327 Deferred income taxes 1,617 2,048 Installment receivables 906 943 Deferred financing fees 599 411 Investments 84 85 Other 112 111 Other Long-Term Assets $ 5,643 $ 5,925

Property And Equipment

Property And Equipment	3 Months Ended
	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Property And Equipment	Property and Equipment Property and equipment consist of the following (in thousands): March 31, 2021 December 31, 2020 Machinery and equipment $ 294,325 $ 294,045 Land, buildings and improvements 28,761 28,509 Capitalized software 20,514 17,527 Furniture and fixtures 9,957 10,001 Leasehold improvements 8,247 8,194 Property and Equipment, gross 361,804 358,276 Accumulated depreciation (304,011) (302,033) Property and Equipment, net $ 57,793 $ 56,243

Goodwill

Goodwill	3 Months Ended
	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill The change in goodwill from December 31, 2020 to March 31, 2021 was due to foreign currency translation. In accordance with Intangibles—Goodwill and Other , ASC 350, goodwill is tested annually for impairment or whenever events or changes in circumstances indicate the carrying value of a reporting unit could be above its fair value.

Intangibles

Intangibles	3 Months Ended
	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Other Intangibles	Intangibles The company's intangibles consist of the following (in thousands): March 31, 2021 December 31, 2020 Historical Accumulated Historical Accumulated Customer lists $ 55,235 $ 55,235 $ 54,502 $ 54,502 Trademarks 25,509 — 25,112 — Developed technology 8,019 7,338 7,924 7,204 Patents 5,558 5,558 5,556 5,556 License agreements 2,909 1,042 2,899 979 Other 1,161 1,152 1,162 1,151 Intangibles $ 98,391 $ 70,325 $ 97,155 $ 69,392 All the company’s intangible assets have been assigned definite lives and continue to be amortized over their useful lives, except for trademarks shown above, which have indefinite lives. The changes in intangible balances reflected on the balance sheet from December 31, 2020 to March 31, 2021 were the result of foreign currency translation on historical cost and accumulated amortization. The company evaluates the carrying value of definite-lived assets annually in the fourth quarter and whenever events or circumstances indicate possible impairment. Definite-lived assets are determined to be impaired if the future undiscounted cash flows expected to be generated by the asset are less than the carrying value. Actual impairment amounts for definite-lived assets are then calculated using a discounted cash flow calculation. Any impairment for indefinite-lived intangible assets is calculated as the difference between the future discounted cash flows expected to be generated by the asset less than the carrying value for the asset. Amortization expense related to intangible assets was $102,000 in the first three months of 2021 and is expected to be $409,000 in 2021, $410,000 in 2022, $410,000 in 2023, $354,000 in 2024, $213,000 in 2025 and $211,000 in 2026. Amortized intangible assets are being amortized on a straight-line basis over remaining lives of 4 to 9 years with a weighted average remaining life of approximately 7 years.

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2021
Payables and Accruals [Abstract]
Accrued Expenses	Accrued Expenses Accrued expenses consist of accruals for the following (in thousands): March 31, 2021 December 31, 2020 Salaries and wages $ 33,399 $ 34,029 Taxes other than income taxes, primarily value added taxes 24,705 32,710 Warranty 11,091 10,991 Professional 10,672 7,375 Interest 3,870 2,076 Freight 3,773 3,190 IT service contracts 3,582 3,799 Derivative liabilities (foreign currency forward exchange contracts) 3,399 1,432 Deferred revenue 3,112 3,516 Product liability, current portion 2,698 2,453 Rebates 2,553 8,644 Severance 865 6,249 Insurance 782 878 Rent 583 585 Supplemental Executive Retirement Program liability 391 391 Other items, principally trade accruals 6,803 7,955 Accrued Expenses $ 112,278 $ 126,273 Generally, the company's products are covered by warranties against defects in material and workmanship for various periods depending on the product from the date of sales to the customer. Certain components carry a lifetime warranty. A provision for estimated warranty cost is recorded at the time of sale based upon actual experience. In addition, the company has sold extended warranties that, while immaterial, require the company to defer the revenue associated with those warranties until earned. The company has established procedures to appropriately defer such revenue. The company continuously assesses the adequacy of its product warranty accrual and makes adjustments as needed. Historical analysis is primarily used to determine the company's warranty reserves. Claims history is reviewed and provisions are adjusted as needed. However, the company does consider other events, such as a product field action and recalls, which could require additional warranty reserve provision. Accrued rebates relate to several volume incentive programs the company offers its customers. The company accounts for these rebates as a reduction of revenue when the products are sold. Rebates are netted against gross accounts receivables. If rebates are in excess of such receivables, they are then classified as accrued expenses. The reduction in accrued rebates from December 31, 2020 to March 31, 2021 primarily relates to payments principally made in the first quarter each year. In the fourth quarter of 2019, the company entered into an agreement with an IT provider to outsource substantially all of the company’s information technology business service activities, including, among other things, support, rationalization and upgrading of the company’s legacy information technology systems and implementation of a global ERP. Accrued expenses related to IT outsourcing are reflected in IT service contracts. The following is a reconciliation of the changes in accrued warranty costs for the reporting period (in thousands): Balance as of January 1, 2021 $ 10,991 Warranties provided during the period 1,471 Settlements made during the period (1,477) Changes in liability for pre-existing warranties during the period, including expirations 106 Balance as of March 31, 2021 $ 11,091

Other Long-Term Obligations

Other Long-Term Obligations	3 Months Ended
	Mar. 31, 2021
Other Liabilities Disclosure [Abstract]
Other Long-Term Obligations	Other Long-Term Obligations Other long-term obligations consist of the following (in thousands): March 31, 2021 December 31, 2020 Deferred income taxes $ 23,605 $ 23,234 Product liability 12,968 12,304 Pension 9,107 9,088 Deferred gain on sale leaseback 5,421 5,502 Supplemental Executive Retirement Plan liability 5,319 5,368 Deferred compensation 5,192 5,318 Uncertain tax obligation including interest 3,135 3,114 Other 6,525 6,546 Other Long-Term Obligations $ 71,272 $ 70,474 On April 23, 2015, the company entered into a real estate sale leaseback transaction which resulted in the company recording an initial deferred gain of $7,414,000, the majority of which is included in Other Long-Term Obligations and will be recognized over the 20-year life of the leases. The gains realized were $78,000 and $75,000 for the three months ended March 31, 2021 and 2020, respectively.

Leases and Commitments (Notes)

Leases and Commitments (Notes)	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Leases of Lessee Disclosure [Text Block]	Leases and Commitments The company reviews new contracts to determine if the contracts include a lease. To the extent a lease agreement includes an extension option that is reasonably certain to be exercised, the company has recognized those amounts as part of the right-of-use assets and lease liabilities. The company combines lease and certain non-lease components, such as common area maintenance, in the calculation of the lease assets and related liabilities. As most lease agreements do not provide an implicit rate, the company uses an incremental borrowing rate (IBR) based on information available at commencement date in determining the present value of lease payments and to help classify the lease as operating or financing. The company calculates its IBR based on the secured rates of the company's recent debt issuances, the credit rating of the company, changes in currencies, lease repayment timing as well as other publicly available data. The company leases a portion of its facilities, transportation equipment, data processing equipment and certain other equipment. These leases have terms from 1 to 20 years and provide for renewal options. Generally, the company is required to pay taxes and normal expenses associated with operating the facilities and equipment. As of March 31, 2021, the company is committed under non-cancelable leases, which have initial or remaining terms in excess of one year and expire on various dates through 2040. On April 23, 2015, the company sold and leased back, under four separate lease agreements, four properties located in Ohio and one property in Florida for net proceeds of $23,000,000, which were used to reduce debt under the U.S. and Canadian Credit Facility . The initial total annual rent for the properties was $2,275,000 and can increase annually over the 20-year term of the leases based on the applicable geographical consumer price index (CPI). Each of the four lease agreements contains three 10-year renewals with the rent for each option term based on the greater of the then-current fair market rent for each property or the then- current rate and increasing annually by the applicable CPI. Under the terms of the lease agreements, the company is responsible for all taxes, insurance and utilities. The company is required to adequately maintain each of the properties and any leasehold improvements will be amortized over the lesser of the lives of the improvements or the remaining lease lives, consistent with any other company leases. In connection with the transaction, the requirements for sale lease-back accounting were met. Accordingly, the company recorded the sale of the properties, removed the related property and equipment from the company's balance sheet, recognized an initial deferred gain of $7,414,000 and an immediate loss of $257,000 related to one property and recorded new lease liabilities. Specifically, the company recorded four finance leases totaling $32,339,000 and one operating lease related to leased land, which was not a material component of the transaction. The gains on the sales of the properties were required to be deferred and recognized over the life of the leases as the property sold is being leased back. The deferred gain is classified under Other Long-Term Obligations on the consolidated balance sheet. The gains realized were $78,000 for the three months ended March 31, 2021 compared to $75,000 for the three months ended March 31, 2020. In December 2018, the company entered into a 20-year lease agreement in Germany. The lease commenced in July 2020. The lease increased the company's finance lease obligation by $36,916,000 and increased the finance lease expense compared to previous periods. In December of 2020, the company entered into a 12.6-year lease agreement in Germany. The lease increased the company's finance lease obligation by $5,561,000 and increased the finance lease expense compared to previous periods. Lease expenses for the three months ended March 31, 2021 and March 31, 2020, respectively, were as follows (in thousands): For the Three Months Ended March 31, 2021 2020 Operating leases $ 1,962 $ 2,243 Variable and short-term leases 1,051 921 Total operating leases $ 3,013 $ 3,164 Finance lease interest cost $ 1,178 $ 328 Finance lease depreciation 1,276 703 Total finance leases $ 2,454 $ 1,031 Future minimum operating and finance lease commitments, as of March 31, 2021, are as follows (in thousands): Finance Operating Leases 2021 $ 6,714 $ 5,433 2022 7,051 4,225 2023 6,947 1,967 2024 6,878 1,360 2025 6,821 1,083 Thereafter 81,091 2,319 Total future minimum lease payments 115,502 16,387 Amounts representing interest (43,572) (2,421) Present value of minimum lease payments 71,930 13,966 Less: current maturities of lease obligations (3,584) (5,610) Long-term lease obligations $ 68,346 $ 8,356 Supplemental cash flow amounts for the three months ended March 31, 2021 were as follows (in thousands): Cash Activity: Cash paid in measurement of amounts for lease liabilities March 31, 2021 Operating leases $ 3,020 Finance leases 2,109 Total $ 5,129 Non-Cash Activity: Right-of-use assets obtained in exchange for lease obligations March 31, 2021 Operating leases $ 3,839 Finance leases 5,975 Total $ 9,814 Weighted-average remaining lease terms and discount rates for finance and operating leases are as follows as of March 31, 2021: March 31, 2021 Weighted-average remaining lease term - finance leases 16.5 years Weighted-average remaining lease term - operating leases 4.7 years Weighted-average discount rate - finance leases 6.50% Weighted-average discount rate - operating leases 7.74%

Revenue Revenue

Revenue Revenue	3 Months Ended
	Mar. 31, 2021
Revenue [Abstract]
Revenue Recognition, Deferred Revenue [Policy Text Block]	Revenue The company has two revenue streams: products and services. Services include repair, refurbishment, preventive maintenance and rental of product. Services for the North America segment include maintenance and repair of products. Services for the Europe segment include repair, refurbishment and preventive maintenance services. Services in All Other, are in the Asia Pacific region, and include rental and repair of products. The following tables disaggregate the company’s revenues by major source and by reportable segment for the three months ended March 31, 2021 and March 31, 2020 (in thousands): Three Months Ended March 31, 2021 Product Service Total Europe $ 109,844 $ 2,931 $ 112,775 North America 75,702 272 75,974 All Other 6,178 1,275 7,453 Total $ 191,724 $ 4,478 $ 196,202 % Split 98% 2% 100% Three Months Ended March 31, 2020 Product Service Total Europe $ 117,685 $ 3,283 $ 120,968 North America 86,764 207 86,971 All Other 9,322 1,179 10,501 Total $ 213,771 $ 4,669 $ 218,440 % Split 98% 2% 100% The company's revenues are principally related to the sale of products, approximately 98%, with the remaining 2% related to services including repair, refurbishment, preventive maintenance and rental of products. While the company has a significant amount of contract types, the sales split by contract type is as follows: general terms and conditions (30%), large national customers (30%), governments, principally pursuant to tender contracts (21%) and other customers including buying groups and independent customers (19%). All product and substantially all service revenues are recognized at a point in time. The remaining service revenue, recognized over time, are reflected in the Europe segment and include multiple performance obligations. For such contracts, the company allocates revenue to each performance obligation based on its relative standalone selling price. The company generally determines the standalone selling price based on the expected cost-plus margin methodology. Revenue is recognized when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the company’s products and services. Revenue is measured as the amount of consideration expected to be received in exchange for transferring product or providing services. The amount of consideration received and revenue recognized by the company can vary as a result of variable consideration terms included in the contracts related to customer rebates, cash discounts and return policies. Customer rebates and cash discounts are estimated based on the most likely amount principle and these estimates are based on historical experience and anticipated performance. In addition, customers have the right to return product within the company’s normal terms policy, and as such the company estimates the expected returns based on an analysis of historical experience. The company adjusts its estimate of revenue at the earlier of when the most likely amount of consideration it expects to receive changes or when the consideration becomes fixed. The company generally does not expect that there will be significant changes to its estimates of variable consideration (see “Receivables” and "Accrued Expenses" in the Notes to the Condensed Consolidated Financial Statements include elsewhere in this report for more detail). Depending on the terms of the contract, the company may defer the recognition of a portion of the revenue at the end of a reporting period to align with transfer of control of the company’s products to the customer. In addition, to the extent performance obligations are satisfied over time, the company defers revenue recognition until the performance obligations are satisfied. As of March 31, 2021 and December 31, 2020, the company had deferred revenue of $3,112,000 and $3,516,000, respectively, related to outstanding performance obligations.

Equity Compensation

Equity Compensation	3 Months Ended
	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
Shareholders' Equity Transactions	Equity Compensation The company’s Common Shares have a $0.25 stated value. The Common Shares and the Class B Common Shares generally have identical rights, terms and conditions and vote together as a single class on most issues, except that the Class B Common Shares have ten votes per share and, in general, can only be transferred to family members or for estate planning purposes. Holders of Class B Common Shares are entitled to convert their shares into Common Shares at any time on a share-for-share basis. When Class B Common Shares are transferred out of a familial relationship, they automatically convert to Common Shares. As of March 31, 2021, 3,667 Class B Common Shares remained outstanding. Prior conversions of Class B Common Shares have virtually eliminated the company’s dual class voting structure. As of March 31, 2021, the holders of the Common Shares represented approximately 99.9% of the company’s total outstanding voting power. Equity Compensation Plan On May 17, 2018, the shareholders of the company approved the Invacare Corporation 2018 Equity Compensation Plan (the “2018 Plan”), which was adopted on March 27, 2018 by the company's Board of Directors (the “Board”). The company’s Board adopted the 2018 Plan in order to authorize additional Common Shares for grant as equity compensation, and to reflect changes to Section 162(m) of the Internal Revenue Code (the “Code”) resulting from the U.S. Tax Cuts and Jobs Act of 2017. Following shareholder approval of the 2018 Plan, all of the Common Shares then-remaining available for issuance under the Invacare Corporation 2013 Equity Compensation Plan (the “2013 Plan”) and all of the Common Shares that were forfeited or remained unpurchased or undistributed upon termination or expiration of awards under the 2013 Plan and under the Invacare Corporation 2003 Performance Plan (the “2003 Plan”), become available for issuance under the 2018 Plan. Awards granted previously under the 2013 Plan and 2003 Plan will remain in effect under their original terms. The 2018 Plan uses a fungible share-counting method, under which each Common Share underlying an award of stock options or stock appreciation rights ("SAR") will count against the number of total shares available under the 2018 Plan as one share; and each Common Share underlying any award other than a stock option or a SAR will count against the number of total shares available under the 2018 Plan as two shares. Shares underlying awards made under the 2003 Plan or 2013 Plan that are forfeited or remain unpurchased or undistributed upon termination or expiration of the awards will become available under the 2018 Plan for use in future awards. Any Common Shares that are added back to the 2018 Plan as the result of forfeiture, termination or expiration of an award granted under the 2018 Plan or the 2013 Plan will be added back in the same manner such shares were originally counted against the total number of shares available under the 2018 Plan or 2013 Plan, as applicable. Each Common Share that is added back to the 2018 Plan due to a forfeiture, termination or expiration of an award granted under the 2003 Plan will be added back as one Common Share. The Compensation and Management Development Committee of the Board (the “Compensation Committee”), in its discretion, may grant an award under the 2018 Plan to any director or employee of the company or an affiliate. As of March 31, 2021, 905,188 Common Shares were available for future issuance under the 2018 Plan in connection with the following types of awards with respect to the company's Common Shares: incentive stock options, nonqualified stock options, SARs, restricted stock, restricted stock units, unrestricted stock and performance shares. The Compensation Committee also may grant performance units that are payable in cash. The Compensation Committee has the authority to determine which participants will receive awards, the amount of the awards and the other terms and conditions of the awards. At March 31, 2021, an aggregate of 376,516 Common Shares underlie awards which were forfeited or expired unexercised under the 2003 and 2013 Plans and thus are available to be transferred under the 2018 Plan. The company has submitted an amendment to the 2018 Plan to shareholders for approval at the company's 2021 annual meeting that, if approved by shareholders, will increase the number of Common Shares authorized for issuance under the 2018 Plan by 2,500,000 additional Common Shares. The 2018 Plan provides that shares granted come from the company's authorized but unissued Common Shares or treasury shares. In addition, the company's stock-based compensation plans allow employee participants to exchange shares for minimum withholding taxes, which results in the company acquiring treasury shares. The amounts of equity-based compensation expense recognized as part of SG&A expenses in All Other in business segment reporting were as follows (in thousands): For the Three Months Ended March 31, 2021 2020 Restricted stock / units $ 912 $ 775 Performance shares / units 668 425 Total stock-based compensation expense $ 1,580 $ 1,200 As of March 31, 2021, unrecognized compensation expense related to equity-based compensation arrangements granted under the company's 2018 Plan and previous plans, which is related to non-vested options and shares, was as follows (in thousands): March 31, 2021 Restricted stock and restricted stock units $ 11,733 Performance shares and performance share units 9,537 Total unrecognized stock-based compensation expense $ 21,270 Total unrecognized compensation cost will be adjusted for future changes in actual and estimated forfeitures and for updated vesting assumptions for the performance share awards (refer to "Stock Options" and "Performance Shares and Performance Share Units" below). No tax benefits for stock compensation were realized during the three months ended March 31, 2021 and 2020, respectively, due to a valuation allowance against deferred tax assets. In accordance with ASC 718, any tax benefits resulting from tax deductions in excess of the compensation expense recognized is classified as a component of financing cash flows. Stock Options Generally, non-qualified stock option awards have a term of ten years and were granted with an exercise price per share equal to the fair market value of the company’s Common Shares on the date of grant. Stock option awards granted in 2017 were performance-based awards which became exercisable based upon achievement of the performance goals established by the Compensation Committee as achieved over a 3-year period end in 2019 which were subject to the Compensation Committee's exercise of negative discretion to reduce the number of options vested based on the progress towards other initiatives. The following table summarizes information about stock option activity for the three months ended March 31, 2021: Weighted Average Options outstanding at January 1, 2021 1,081,804 $ 16.07 Forfeited (38,200) 17.01 Options outstanding at March 31, 2021 1,043,604 $ 16.03 Options exercise price range at March 31, 2021 $ 12.15 to $ 33.36 Options exercisable at March 31, 2021 1,043,604 Shares available for grant at March 31, 2021* 905,188 ________ * Shares available for grant under the 2018 Plan as of March 31, 2021 reduced by net restricted stock and restricted stock unit and performance share and performance share unit award activity of 2,671,108 shares. The following table summarizes information about stock options outstanding at March 31, 2021: Options Outstanding Options Exercisable Exercise Prices Number Weighted Average Weighted Average Number Weighted Average $12.15 – $20.00 750,159 4.7 $ 12.69 750,159 $ 12.69 $20.01 – $30.00 288,949 0.4 24.45 288,949 24.45 $30.01 – $33.36 4,496 0.1 33.36 4,496 33.36 Total 1,043,604 3.5 $ 16.03 1,043,604 $ 16.03 The 2018 Plan provides for a one-year minimum vesting period for stock options and, generally, options must be exercised within ten years from the date granted. No stock options were issued in 2021 or 2020. Restricted Stock and Restricted Stock Units The following table summarizes information about restricted stock and restricted stock units (primarily for non-U.S. recipients): Weighted Average Fair Value Stock / Units unvested at 1,145,058 $ 8.62 Granted 617,707 8.48 Forfeited (8,190) 9.38 Stock / Units unvested at 1,754,575 $ 8.57 The restricted awards generally vest ratably over the three years after the award date. Unearned restricted stock compensation, determined as the market value of the shares at the date of grant, is being amortized on a straight-line basis over the vesting period. Performance Shares and Performance Share Units The following table summarizes information about performance shares and performance share units (primarily for non-U.S. recipients): Weighted Average Fair Value Shares / Units unvested at January 1, 2021 1,026,785 $ 8.55 Granted 471,819 8.49 Shares / Units unvested at 1,498,604 $ 8.53 During the three months ended March 31, 2021, performance shares and performance share units (for non-U.S. recipients) were granted as performance awards with a three performance shares that vest based upon the levels of achievement which may range between 0% and 150% of the target number of shares with the target being 100% of the initial grant. The fair value of the performance awards is based on the stock price on the date of grant discounted for the estimated value of dividends foregone as the awards are not eligible for dividends except to the extent vested. The grant fair value is further updated each reporting period while variable accounting applies. The company assesses the probability that the performance targets will be met with expense recognized whenever it is probable that at least the minimum performance criteria will be achieved. Depending upon the company's assessment of the probability of achievement of the goals, the company may not recognize any expense associated with performance awards in a given period, may reverse prior expense recorded or record additional expense to recognize the cumulative estimated achievement level of proportionate term of the award. Performance award compensation expense is generally expected to be recognized over three years. The company continues to recognize expense related to the awards granted in 2019, 2020 and 2021 as it is considered probable that the performance goals for those awards will be met.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss) by Component	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss) by Component	Accumulated Other Comprehensive Income (Loss) by Component Changes in accumulated other comprehensive income ("OCI") (in thousands): Foreign Currency Long-Term Notes Defined Benefit Plans Derivatives Total December 31, 2020 $ 50,329 $ (517) $ (3,674) $ (702) $ 45,436 OCI before reclassifications 2,802 2,875 470 (1,218) 4,929 Amount reclassified from accumulated OCI — — (121) 426 305 Net current-period OCI 2,802 2,875 349 (792) 5,234 March 31, 2021 $ 53,131 $ 2,358 $ (3,325) $ (1,494) $ 50,670 Foreign Currency Long-Term Notes Defined Benefit Plans Derivatives Total December 31, 2019 $ 8,898 $ (2,491) $ (3,299) $ 20 $ 3,128 OCI before reclassifications 1,664 (5,858) (598) (261) (5,053) Amount reclassified from accumulated OCI — — 429 119 548 Net current-period OCI 1,664 (5,858) (169) (142) (4,505) March 31, 2020 $ 10,562 $ (8,349) $ (3,468) $ (122) $ (1,377) Reclassifications out of accumulated OCI were as follows (in thousands): Amount reclassified from OCI Affected line item in the Statement of Comprehensive (Income) Loss For the Three Months Ended March 31, 2021 2020 Defined Benefit Plans Service and interest costs $ (121) $ 429 Selling, general and administrative expenses Tax — — Income tax provision Total after tax $ (121) $ 429 Derivatives Foreign currency forward contracts hedging sales $ 22 $ 115 Net sales Foreign currency forward contracts hedging purchases 452 35 Cost of products sold Total loss before tax 474 150 Tax (48) (31) Income tax benefit Total after tax $ 426 $ 119

Charges Related To Restructurin

Charges Related To Restructuring Activities	3 Months Ended
	Mar. 31, 2021
Restructuring and Related Activities [Abstract]
Charges Related To Restructuring Activities	Charges Related to Restructuring Activities The company's restructuring charges were originally necessitated primarily by continued declines in Medicare and Medicaid reimbursement by the U.S. government, as well as similar healthcare reimbursement pressures abroad, which negatively affect the company's customers (e.g. home health care providers) and continued pricing pressures faced by the company due to the outsourcing by competitors to lower cost locations. Restructuring decisions were also the result of reduced profitability in each of the segments. Restructuring actions have continued into 2021. For the three months ended March 31, 2021, charges totaled $1,552,000 which were related to North America of $822,000 and Europe of $730,000. In North America costs were incurred related to severance. The European charges were for severance costs of $454,000 and contract terminations of $276,000, primarily related to the closure of a German manufacturing facility. Payments for the three months ended March 31, 2021 were $6,283,000 and the cash payments were funded with the company's cash on hand. The 2021 charges are expected to be paid out within 24 months. For the three months ended March 31, 2020, charges totaled $1,392,000 which were related to North America of $691,000, Europe of $665,000 and All Other of $36,000. In North America and All Other, costs were incurred related to severance. The European charges were for severance costs $592,000 and contract terminations $73,000. Payments for the three months ended March 31, 2020 were $1,870,000 and the cash payments were funded with company's cash on hand. Most of the 2020 charges have been paid out. There have been no material changes in accrued balances related to the charges, either as a result of revisions to the plans or changes in estimates. In addition, the savings anticipated as a result of the company's restructuring plans have been or are expected to be achieved, primarily resulting in reduced salary and benefit costs principally impacting selling, general and administrative expenses, and to a lesser extent, costs of products sold. To date, the company's liquidity has been sufficient to absorb these charges and payments. A progression by reporting segment of the accruals recorded as a result of the restructuring for the three months ended March 31, 2021 is as follows (in thousands): Severance Contract Terminations Total December 31, 2020 Balances North America $ 179 $ — $ 179 Europe 5,904 4 5,908 All Other 166 — 166 Total 6,249 4 6,253 Charges North America 822 — 822 Europe 454 276 730 All Other — — — Total 1,276 276 1,552 Payments North America (236) — (236) Europe (6,047) — (6,047) All Other — — — Total (6,283) — (6,283) March 31, 2021 Balances North America 765 — 765 Europe 311 280 591 All Other 166 — 166 Total $ 1,242 $ 280 $ 1,522

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The company had an effective tax rate of 15.4% on losses and 74.2% on earnings before tax for the three months ended March 31, 2021 and March 31, 2020, respectively, compared to an expected benefit for the three months ended March 31, 2021 and an expected expense for the three months ended March 31, 2020 of 21.0% on the pre-tax loss and earnings for each period. The company's effective tax rate for the three months ended March 31, 2021 and March 31, 2020 were unfavorable as compared to the U.S. federal statutory rate, principally due to the negative impact of the company not being able to record tax benefits related to the significant losses in countries which had tax valuation allowances. The effective tax rate was increased for the three months ended March 31, 2021 and March 31, 2020 by certain taxes outside the United States, excluding countries with tax valuation allowances, that were at an effective rate higher than the U.S. statutory rate, except for the gain on the disposition of Dynamic Controls which was not taxable locally for the three months ended March 31, 2020 . In addition, the company had accrued withholding taxes on earnings of its Chinese subsidiary based on the expectation of not permanently reinvesting those earnings. The sale of this entity, without such distribution resulted in the reversal of this accrual in the amount of $988,000 for the three months ended March 31, 2020.

Net Earnings (Loss) Per Common

Net Earnings (Loss) Per Common Share	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Net Earnings (Loss) Per Common Share	Net Income (Loss) Per Common Share The following table sets forth the computation of basic and diluted net earnings (loss) per common share for the periods indicated. (In thousands except per share data) For the Three Months Ended March 31, 2021 2020 Basic Weighted average common shares outstanding 34,495 33,784 Net income (loss) $ (14,044) $ 732 Net income (loss) per common share $ (0.41) $ 0.02 Diluted Weighted average common shares outstanding 34,495 33,784 Share options and awards 715 69 Weighted average common shares assuming dilution 35,210 33,853 Net income (loss) $ (14,044) $ 732 Net income (loss) per common share * $ (0.41) $ 0.02 ________ * Net income (loss) per common share assuming dilution calculated utilizing weighted average shares outstanding-basic for the periods in which there was a net loss. At March 31, 2021 and March 31, 2020, shares associated with equity compensation awards of 1,100,648 and 2,366,261, respectively, were excluded from the average common shares assuming dilution as incremental shares were anti-dilutive. At March 31, 2021, the majority of the anti-dilutive incremental shares were awards granted at an exercise price of $24.45, which was higher than the average fair market value price of $9.32. At March 31, 2020, the majority of the anti-dilutive incremental shares were awards granted at an exercise price of $24.45 or above, which was higher than the average fair market value price of $7.75. For the three months ended March 31, 2021 and March 31, 2020, respectively, no shares were included in the common shares assuming dilution related to the company's issued warrants as the average market price of the company shares for these periods did not exceed the strike price of the warrants. Further, upon adoption of ASU 2020-06, effective in 2021 for the company, use of the if-converted earnings per share method is required. However, no shares were included in the common shares assuming dilution for the three months ended March 31, 2021 related to the company's convertible senior notes as conversion prices were above the company's

Concentration Of Credit Risk

Concentration Of Credit Risk	3 Months Ended
	Mar. 31, 2021
Risks and Uncertainties [Abstract]
Concentration Of Credit Risk	Concentration of Credit Risk The company manufactures and distributes durable medical equipment to the home health care, retail and extended care markets. The company performs credit evaluations of its customers’ financial condition. The company utilizes De Lage Landen, Inc. (“DLL”), a third-party financing company, to provide lease financing to Invacare's U.S. customers. The DLL agreement provides for direct leasing between DLL and the Invacare customer. The company retains a recourse obligation of $1,128,000 at March 31, 2021 to DLL for events of default under the contracts, which total $8,951,000 at March 31, 2021. Guarantees, ASC 460, requires the company to record a guarantee liability as it relates to the limited recourse obligation. As such, the company has recorded a liability for this guarantee obligation within accrued expenses. The company's recourse is reevaluated by DLL biannually, considers activity between the biannual dates and excludes any receivables purchased by the company from DLL. The company monitors the collections status of these contracts and has provided amounts for estimated losses in its allowances for doubtful accounts in accordance with Receivables, ASC 310-10-05-4 . Credit losses are provided for in the financial statements. Substantially all the company’s receivables are due from health care, medical equipment providers and long-term care facilities located throughout the United States, Australia, Canada, New Zealand and Europe or also direct from governmental entities in certain countries. A significant portion of products sold to dealers, both foreign and domestic, is ultimately funded through government reimbursement programs such as Medicare and Medicaid. The company has also seen a significant shift in reimbursement to customers from managed care entities. As a consequence, changes in these programs can have an adverse impact on dealer liquidity and profitability. In addition, reimbursement guidelines in the home health care industry have a substantial impact on the nature and type of equipment an end user can obtain as well as the timing of reimbursement and, thus, affect the product mix, pricing and payment patterns of the company’s customers.

Derivatives

Derivatives	3 Months Ended
	Mar. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	Derivatives ASC 815 requires companies to recognize all derivative instruments in the consolidated balance sheet as either assets or liabilities at fair value. The accounting for changes in fair value of a derivative is dependent upon whether or not the derivative has been designated and qualifies for hedge accounting treatment and the type of hedging relationship. For derivatives designated and qualifying as hedging instruments, the company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. Cash Flow Hedging Strategy The company uses derivative instruments in an attempt to manage its exposure to transactional foreign currency exchange risk. Foreign forward exchange contracts are used to manage the price risk associated with forecasted sales denominated in foreign currencies and the price risk associated with forecasted purchases of inventory over the next twelve months. The company recognizes its derivative instruments as assets or liabilities in the consolidated balance sheet measured at fair value. A majority of the company’s derivative instruments are designated and qualify as cash flow hedges. Accordingly, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. The remaining gain or loss on the derivative instrument in excess of the cumulative change in the fair value of the hedged item, if any, is recognized in current earnings during the period of change. To protect against increases/decreases in forecasted foreign currency cash flows resulting from inventory purchases/sales over the next year, the company utilizes foreign currency forward contracts to hedge portions of its forecasted purchases/sales denominated in foreign currencies. The gains and losses are included in cost of products sold and selling, general and administrative expenses on the consolidated statement of comprehensive income (loss). If it is later determined that a hedged forecasted transaction is unlikely to occur, any prospective gains or losses on the forward contracts would be recognized in earnings. The company does not expect any material amount of hedge ineffectiveness related to forward contract cash flow hedges during the next twelve months. The company has historically not recognized any material amount of ineffectiveness related to forward contract cash flow hedges because the company generally limits its hedges to between 50% and 90% of total forecasted transactions for a given entity’s exposure to currency rate changes and the transactions hedged are recurring in nature. Furthermore, most of the hedged transactions are related to intercompany sales and purchases for which settlement occurs on a specific day each month. Forward contracts with a total notional amount in USD of $26,667,000 and $42,894,000 matured for the three months ended March 31, 2021 and March 31, 2020, respectively. Outstanding foreign currency forward exchange contracts qualifying and designated for hedge accounting treatment were as follows (in thousands USD): March 31, 2021 December 31, 2020 Notional Unrealized Notional Unrealized USD / CHF 1,240 (1) 1,675 (11) USD / EUR 44,156 (902) 56,187 (636) USD / GBP 1,892 (97) 2,467 (19) USD / SEK 2,009 (60) 2,658 (41) USD / MXN 2,492 258 2,230 334 EUR / CHF 3,847 56 5,037 10 EUR / GBP 14,796 (488) 19,060 44 EUR / SEK 7,586 (96) 10,162 (73) EUR / NOK 3,532 (116) 4,167 (64) AUD / NZD 614 (18) 781 (13) DKK / SEK 2,273 17 3,329 9 NOK / SEK 2,461 (66) 3,431 (50) AUD / THB 3,888 (260) 4,963 (221) NZD / THB 1,381 (55) 1,755 (55) USD / THB 3,114 89 4,152 (56) EUR / THB 1,034 12 1,332 18 GBP / THB 652 38 842 10 $ 96,967 $ (1,689) $ 124,228 $ (814) Derivatives Not Qualifying or Designated for Hedge Accounting Treatment The company utilizes foreign currency forward contracts that are not designated as hedges in accordance with ASC 815. These contracts are entered into to eliminate the risk associated with the settlement of short-term intercompany trading receivables and payables between Invacare Corporation and its foreign subsidiaries. The currency forward contracts are entered into at the same time as the intercompany receivables or payables are created so that upon settlement, the gain/loss on the settlement is offset by the gain/loss on the foreign currency forward contract. No material net gain or loss was realized by the company in 2021 or 2020 related to these contracts and the associated short-term intercompany trading receivables and payables. Foreign currency forward exchange contracts not qualifying or designated for hedge accounting treatment, as well as ineffective hedges, entered into in 2021 and 2020, respectively, and outstanding were as follows (in thousands USD): March 31, 2021 December 31, 2020 Notional Gain Notional Gain AUD / USD $ 5,776 $ 111 $ 6,046 $ (159) CAD / USD 13,086 (139) 8,320 88 DKK / USD 8,859 (320) 8,690 207 GBP / USD 16,947 (418) 16,062 338 NOK / USD 9,522 (175) 9,053 264 AUD / NZD 6,497 (46) 6,579 (35) $ 60,687 $ (987) $ 54,750 $ 703 The fair values of the company’s derivative instruments were as follows (in thousands): March 31, 2021 December 31, 2020 Assets Liabilities Assets Liabilities Derivatives designated as hedging instruments under ASC 815 Foreign currency forward exchange contracts $ 470 $ 2,159 $ 424 $ 1,238 Derivatives not designated as hedging instruments under ASC 815 Foreign currency forward exchange contracts 253 1,240 897 194 Total derivatives $ 723 $ 3,399 $ 1,321 $ 1,432 The fair values of the company’s foreign currency forward exchange contract assets and liabilities are included in Other Current Assets and Accrued Expenses, respectively in the Condensed Consolidated Balance Sheets. The effect of derivative instruments on Accumulated Other Comprehensive Income (OCI) and the Condensed Statement of Comprehensive Income (Loss) was as follows (in thousands): Derivatives (foreign currency forward exchange contracts) in ASC 815 cash flow hedge Amount of Gain Amount of Gain (Loss) Amount of Gain (Loss) Three months ended March 31, 2021 Foreign currency forward exchange contracts $ (1,218) $ (426) $ — Three months ended March 31, 2020 Foreign currency forward exchange contracts $ (261) $ (119) $ 64 Derivatives (foreign currency forward exchange contracts) not designated as hedging Amount of Gain (Loss) Three months ended March 31, 2021 Foreign currency forward exchange contracts $ (987) Three months ended March 31, 2020 Foreign currency forward exchange contracts $ (724) The gains or losses recognized as the result of the settlement of cash flow hedge foreign currency forward contracts are recognized in net sales for hedges of inventory sales and in cost of products sold for hedges of inventory purchases. For the three months ended March 31, 2021, net sales were increased by $22,000 while cost of products sold was increased by $452,000 for net pre-tax realized loss of $474,000. For the three months ended March 31, 2020, net sales were decreased by $115,000 while cost of products sold was increased by $35,000 for net realized pre-tax loss of $150,000. A loss of $987,000 was recognized in selling, general and administrative (SG&A) expenses for the three months ended March 31, 2021 compared to a loss of $724,000 for the three months ended March 31, 2020 related to forward contracts not designated as hedging instruments. The forward contracts were entered into to offset gains/losses that were also recorded in SG&A expenses on intercompany trade receivables or payables. The gains/losses on the non-designated hedging instruments were substantially offset by gains/losses on intercompany trade payables. The company's derivative agreements provide the counterparties with a right of set off in the event of a default. The right of set off would enable the counterparty to offset any net payment due by the counterparty to the company under the applicable agreement by any amount due by the company to the counterparty under any other agreement. For example, the terms of the agreement would permit a counterparty to a derivative contract that is also a lender under the company's Credit Agreement to reduce any derivative settlement amounts owed to the company under the derivative contract by any amounts owed to the counterparty by the company under the Credit Agreement. In addition, the agreements contain cross-default provisions that could trigger a default by the company under the agreement in the event of a default by the company under another agreement with the same counterparty. The company presents derivatives on a net basis in its financial statements for those subject to provisions that are similar to master netting agreements.

Fair Values

Fair Values	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Values Pursuant to ASC 820, the inputs used to derive the fair value of assets and liabilities are analyzed and assigned a level I, II or III priority, with level I being the highest and level III being the lowest in the hierarchy. Level I inputs are quoted prices in active markets for identical assets or liabilities. Level II inputs are quoted prices for similar assets or liabilities in active markets: quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. Level III inputs are based on valuations derived from valuation techniques in which one or more significant inputs are unobservable. The following table provides a summary of the company’s assets and liabilities that are measured on a recurring basis (in thousands): Basis for Fair Value Measurements at Reporting Date Quoted Prices in Active Significant Other Significant Other Level I Level II Level III March 31, 2021 Forward exchange contracts—net — $ (2,676) — December 31, 2020 Forward exchange contracts—net — $ (111) — The carrying values and fair values of the company’s financial instruments are as follows (in thousands): March 31, 2021 December 31, 2020 Carrying Value Fair Value Carrying Value Fair Value Cash and cash equivalents $ 86,052 $ 86,052 $ 105,298 $ 105,298 Other investments 84 84 85 85 Installment receivables, net of reserves 1,145 1,145 1,322 1,322 Forward contracts in Other Current Assets 723 723 1,321 1,321 Forward contracts in Accrued Expenses (3,399) (3,399) (1,432) (1,432) Total debt (including current maturities of long-term debt) * (288,590) (287,592) (245,053) (237,948) 2021 Notes — — (1,242) (1,264) 2022 Notes (2,627) (2,480) (73,869) (70,633) Series I 2024 Notes (71,939) (70,377) (62,984) (60,035) Series II 2024 Notes (75,334) (75,510) (64,919) (64,090) 2026 Notes (117,786) (118,874) — — Other (20,904) (20,351) (42,039) (41,926) ________ * The company's total debt is shown net of applicable discounts and fees associated with the convertible senior notes due in 2021, 2022, 2024 and 2026 on the company's condensed consolidated balance sheet. Accordingly, the fair values of the convertible senior notes due in 2021, 2022, 2024 and 2026 included in the long-term debt presented in this table are also shown net of the discounts and fees. Discount balances applicable to the company's convertible senior notes were eliminated upon adoption of ASU 2020-06 on January 1, 2021, but are included in the balances above for the period prior to adoption. Refer to Long-Term Debt footnote for discount balances by convertible senior notes series. Total debt excludes operating and finance leases obligations. The company, in estimating its fair value disclosures for financial instruments, used the following methods and assumptions: Cash, cash equivalents: The carrying value reported in the balance sheet for cash, cash equivalents equals its fair value. Other investments: The company has an investment in a limited partnership, which is accounted for using the cost method, adjusted for any estimated declines in value. The investment was acquired in private placement and there is no quoted market price or stated rate of return. The company does not have the ability to easily sell the investment. The company completes an evaluation of the residual value related to such investments in the fourth quarter of each year. Installment receivables: The carrying value reported in the balance sheet for installment receivables approximates its fair value. The interest rates associated with these receivables have not varied significantly since inception. Management believes that after consideration of the credit risk, the net book value of the installment receivables approximates market value. Total debt: Fair value for the company’s convertible debt is based on quoted market-based estimates as of the end of the period, while the revolving credit facility fair value is based upon an estimate of the market for similar borrowing arrangements. The fair values are deemed to be categorized as Level 2 in the fair value hierarchy. Other total debt is primarily attributable to credit facilities borrowings where the carrying value reported in the balance approximates its fair value and the CARES Act Loan which utilizes the fair value factor of the 2022 Notes to approximate fair value.

Business Segments

Business Segments	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Business Segments	Business Segments The company operates in two primary business segments: North America and Europe with each selling the company's primary product categories, which include: lifestyle, mobility and seating and respiratory therapy products. Sales in Asia Pacific are reported in All Other and include products similar to those sold in North America and Europe. The accounting policies of each segment are the same as those described in the summary of significant accounting policies for the company's consolidated financial statements. Intersegment sales and transfers are based on the costs to manufacture plus a reasonable profit element. Segment performance is measured and resources are allocated based on a number of factors, with the primary income or loss measure being segment operating income (loss). Segment operating income (loss) represents net sales less cost of products sold less selling general and administrative expenses. Segment operating income (loss) excludes unallocated corporate general and administrative expenses not allocated to the segments and intersegment sales and profit eliminations, which are included in All Other. In addition, segment operating income (loss) further excludes charges related to restructuring activities, asset impairment and gain on sale of business (as applicable). This performance measure, segment operating income (loss), is used by the Chief Operating Decision Maker (CODM) for purposes of making decisions about allocating resources to a segment and assessing its performance. In addition, this metric is reviewed by the company's Board of Directors regarding segment performance and is a key metric in the performance management assessment of the company's employees. The information by segment is as follows (in thousands): For the Three Months Ended March 31, 2021 2020 Revenues from external customers Europe $ 112,775 $ 120,968 North America 75,974 86,971 All Other (Asia Pacific) 7,453 10,501 Consolidated $ 196,202 $ 218,440 Intersegment revenues Europe $ 5,308 $ 4,226 North America 14,195 20,482 All Other (Asia Pacific) — 2,529 Consolidated $ 19,503 $ 27,237 Restructuring charges before income taxes Europe $ 730 $ 665 North America 822 691 All Other — 36 Consolidated $ 1,552 $ 1,392 Operating income (loss) Europe $ 3,832 $ 6,850 North America (2,375) (2,045) All Other (5,640) (3,555) Charge expense related to restructuring activities (1,552) (1,392) Gain on sale of business — 9,590 Consolidated operating income (loss) (5,735) 9,448 Loss on debt extinguishment including debt finance charges and associated fees (709) — Net interest expense (5,730) (6,616) Earnings (Loss) before income taxes $ (12,174) $ 2,832 Net sales by product, are as follows (in thousands): For the Three Months Ended March 31, 2021 2020 Europe Lifestyle $ 58,298 $ 58,303 Mobility and Seating 44,222 52,778 Respiratory Therapy 6,038 4,931 Other(1) 4,217 4,956 $ 112,775 $ 120,968 North America Lifestyle $ 36,185 $ 42,541 Mobility and Seating 22,733 29,574 Respiratory Therapy 16,784 14,649 Other(1) 272 207 $ 75,974 $ 86,971 All Other (Asia Pacific) Mobility and Seating $ 3,218 $ 5,435 Lifestyle 2,524 3,132 Respiratory Therapy 282 533 Other(1) 1,429 1,401 $ 7,453 $ 10,501 Total Consolidated $ 196,202 $ 218,440 ________________________ (1) Includes various services, including repair services, equipment rentals and external contracting.

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies General In the ordinary course of its business, the company is a defendant in a number of lawsuits, primarily product liability actions in which various plaintiffs seek damages for injuries allegedly caused by defective products. All the product liability lawsuits that the company faces in the United States have been referred to the company's captive insurance company and/or excess insurance carriers while all non-U.S. lawsuits have been referred to the company's commercial insurance carriers. All such lawsuits are generally contested vigorously. The coverage territory of the company's insurance is worldwide with the exception of those countries with respect to which, at the time the product is sold for use or at the time a claim is made, the U.S. government has suspended or prohibited diplomatic or trade relations. The amount recorded for identified contingent liabilities is based on estimates. Amounts recorded are reviewed periodically and adjusted to reflect additional technical and legal information that becomes available. Actual costs to be incurred in future periods may vary from the estimates, given the inherent uncertainties in evaluating certain exposures. As a medical device manufacturer, the company is subject to extensive government regulation, including numerous laws directed at preventing fraud and abuse and laws regulating reimbursement under various government programs. The marketing, invoicing, documenting, developing, testing, manufacturing, labeling, promoting, distributing and other practices of health care suppliers and medical device manufacturers are all subject to government scrutiny. Most of the company's facilities are subject to inspection at any time by the FDA or similar medical device regulatory agencies in other jurisdictions. Violations of law or regulations can result in administrative, civil and criminal penalties and sanctions, which could have a material adverse effect on the company's business. Medical Device Regulatory Matters The FDA in the United States and comparable medical device regulatory authorities in other jurisdictions regulate virtually all aspects of the marketing, invoicing, documenting, development, testing, manufacturing, labeling, promotion, distribution and other practices regarding medical devices. The company and its products are subject to the laws and regulations of the FDA and other regulatory bodies in the various jurisdictions where the company's products are manufactured or sold. The company's failure to comply with the regulatory requirements of the FDA and other applicable medical device regulatory requirements can subject the company to administrative or judicially imposed sanctions or enforcement actions. These sanctions include injunctions, consent decrees, warning letters, civil penalties, criminal penalties, product seizure or detention, product recalls and total or partial suspension of production. In December 2012, the company became subject to a consent decree of injunction filed by the FDA with respect to the company's Corporate facility and its Taylor Street manufacturing facility in Elyria, Ohio. The consent decree initially limited the company's (i) manufacture and distribution of power and manual wheelchairs, wheelchair components and wheelchair sub-assemblies at or from its Taylor Street manufacturing facility, except in verified cases of medical necessity, (ii) design activities related to wheelchairs and power beds that take place at the impacted Elyria facilities and (iii) replacement, service and repair of products already in use from the Taylor Street manufacturing facility. Under the terms of the consent decree, in order to resume full operations, the company had to successfully complete independent, third-party expert certification audits at the impacted Elyria facilities, comprising three distinct certification reports separately submitted to, and subject to acceptance by, the FDA; submit its own report to the FDA; and successfully complete a reinspection by the FDA of the company's Corporate and Taylor Street facilities. On July 24, 2017, following its June 2017 reinspection of the Corporate and Taylor Street facilities, the FDA notified the company that it is in substantial compliance with the FDA Act, FDA regulations and the terms of the consent decree and, that the company was permitted to resume full operations at those facilities including the resumption of unrestricted sales of products made in those facilities. The consent decree will continue in effect for at least five years from July 24, 2017, during which time the company's Corporate and Taylor Street facilities must complete two semi-annual audits in the first year and then four annual audits in the next four years performed by a company-retained expert firm. The expert audit firm will determine whether the facilities remain in continuous compliance with the FDA Act, FDA regulations and the terms of the consent decree. The FDA has the authority to inspect these facilities and any other FDA registered facility, at any time. The FDA has continued to actively inspect the company's facilities, other than through the processes established under the consent decree. The company expects that the FDA will, from time to time, inspect substantially all the company's domestic and foreign FDA-registered facilities. The results of regulatory claims, proceedings, investigations, or litigation are difficult to predict. An unfavorable resolution or outcome of any FDA warning letters or inspectional observations, or other FDA enforcement related to company facilities, could materially and adversely affect the company's business, financial condition, and results of operations. The limitations previously imposed by the FDA consent decree negatively affected net sales in the North America segment and, to a certain extent, the Asia Pacific region beginning in 2012. The limitations led to delays in new product introductions. Further, uncertainty regarding how long the limitations would be in effect limited the company's ability to renegotiate and bid on certain customer contracts and otherwise led to a decline in customer orders. Although the company has been permitted to resume full operations at the Corporate and Taylor Street facilities, the negative effect of the consent decree on customer orders and net sales in the North America segment and Asia Pacific region has been considerable, and it is uncertain as to whether, or how quickly, the company will be able to rebuild net sales to more typical historical levels, irrespective of market conditions. Accordingly, when compared to the company's 2010 results, the previous limitations in the consent decree had, and likely may continue to have, a material adverse effect on the company's business, financial condition and results of operations. Warranty Matters The company's warranty reserves are subject to adjustment in future periods based on historical analysis of warranty claims and as new developments occur that may change the company's estimates related to specific product recalls. Refer to Current Liabilities in the Notes to the Condensed Consolidated Financial Statements for the total provision amounts and a reconciliation of the changes in the warranty accrual. Any of the above contingencies could have an adverse impact on the company's financial condition or results of operations. For additional information regarding the consent decree, other regulatory matters, and risks and trends that may impact the company’s financial condition or results of operations, please see the following sections of the company's Annual Report on Form 10-K for the year ended December 31, 2020: Item 1. Business - Government Regulation and Item 1A. Risk Factors; Item 3. Legal Proceedings; and Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources.

Accounting Policies (Policies)

Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation: The condensed consolidated financial statements include the accounts of the company and its wholly owned subsidiaries and include all adjustments, which were of a normal recurring nature, necessary to present fairly the financial position of the company as of March 31, 2021 and the results of its operations and changes in its cash flow for the three months ended March 31, 2021 and 2020, respectively. Certain foreign subsidiaries, represented by the European segment, are consolidated using a February 28 quarter end to meet filing deadlines. No material subsequent events have occurred related to the European segment, which would require disclosure or adjustment to the company's financial statements. All significant intercompany transactions are eliminated. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the full year.
Use of Estimates	Use of Estimates: The condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States, which require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from these estimates.
Recent Accounting Pronouncements	Recent Accounting Pronouncements (Already Adopted): In August 2020, the FASB issued ASU 2020-06 "Debt with Conversion and Other Options" (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity's Own Equity (Subtopic 815-40)", which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. ASU 2020-06 removes from U.S. GAAP the separation models for (1) convertible debt with a cash conversion feature (CCF) and (2) convertible instrument with a beneficial conversion feature (BCF). As a result, after adopting the ASU’s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC 815 or (2) a convertible debt instrument was issued at a substantial premium. The guidance may be early adopted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The company adopted ASU 2020-06 effective January 1, 2021, using the modified retrospective method, which resulted in the removal of convertible debt discounts of $25,218,000,
New Accounting Pronouncements, Not yet Adopted	Recent Accounting Pronouncements (Not Yet Adopted):

Divested Businesses (Tables)

Divested Businesses (Tables)	2 Months Ended
	Mar. 07, 2020
Divested Businesses [Abstract]
Assets and Liabilities of Divested Business [Table Text Block]	The assets and liabilities of Dynamic Controls as of March 7, 2020 consisted of the following (in thousands): March 7, 2020 Trade receivables, net $ 4,129 Inventories, net 3,082 Other assets 855 Property and equipment, net 600 Operating lease assets, net 2,127 Total assets $ 10,793 Accounts payable $ 4,692 Accrued expenses 2,473 Current taxes payable 41 Current portion of operating lease obligations 366 Long-term obligations 1,019 Total liabilities $ 8,591

Receivables (Tables)

Receivables (Tables)	3 Months Ended
	Mar. 31, 2021
Receivables [Abstract]
Schedule of Accounts Receivable	Receivables consist of the following (in thousands): March 31, 2021 December 31, 2020 Accounts receivable, gross $ 118,278 $ 131,055 Customer rebate reserve (8,914) (10,730) Cash discount reserves (4,995) (7,320) Allowance for doubtful accounts (4,172) (4,031) Other, principally returns and allowances reserves (424) (386) Accounts receivable, net $ 99,773 $ 108,588
Schedule for Allowance for Credit Losses	The movement in the trade receivables allowance for doubtful accounts was as follows (in thousands): Three Months Ended Balance as of beginning of period $ 4,031 Current period provision 131 Recoveries (direct write-offs), net 10 Balance as of end of period $ 4,172
Schedule of Installment Receivables	Installment receivables consist of the following (in thousands): March 31, 2021 December 31, 2020 Current Long- Total Current Long- Total Installment receivables $ 455 $ 1,057 $ 1,512 $ 704 $ 1,105 $ 1,809 Allowance for doubtful accounts (216) (151) (367) (325) (162) (487) Installment receivables, net $ 239 $ 906 $ 1,145 $ 379 $ 943 $ 1,322
Schedule of Installment Receivables Allowance for Doubtful Accounts	The movement in the installment receivables allowance for doubtful accounts was as follows (in thousands): Three Months Ended Year Ended December 31, 2020 Balance as of beginning of period $ 487 $ 1,514 Current period provision (benefit) (86) 66 Direct write-offs charged against the allowance (34) (1,093) Balance as of end of period $ 367 $ 487
Schedule of Installment Receivables by Class	Installment receivables by class as of March 31, 2021 consist of the following (in thousands): Total Unpaid Related Interest U.S. Impaired installment receivables with a related allowance recorded $ 486 $ 486 $ 367 $ — Asia Pacific Non-Impaired installment receivables with no related allowance recorded 1,026 1,026 — — Total Non-Impaired installment receivables with no related allowance recorded 1,026 1,026 — — Impaired installment receivables with a related allowance recorded 486 486 367 — Total installment receivables $ 1,512 $ 1,512 $ 367 $ — Installment receivables by class as of December 31, 2020 consist of the following (in thousands): Total Unpaid Related Interest U.S. Impaired installment receivables with a related allowance recorded $ 615 $ 615 $ 487 $ — Asia Pacific Non-impaired installment receivables with no related allowance recorded 1,194 1,194 — — Canada Non-impaired installment receivables with no related allowance recorded — — — 29 Total Non-impaired installment receivables with no related allowance recorded 1,194 1,194 — 29 Impaired installment receivables with a related allowance recorded 615 615 487 — Total installment receivables $ 1,809 $ 1,809 $ 487 $ 29
Schedule of Financing Receivables	Installment receivables by class as of March 31, 2021 consist of the following (in thousands): Total Unpaid Related Interest U.S. Impaired installment receivables with a related allowance recorded $ 486 $ 486 $ 367 $ — Asia Pacific Non-Impaired installment receivables with no related allowance recorded 1,026 1,026 — — Total Non-Impaired installment receivables with no related allowance recorded 1,026 1,026 — — Impaired installment receivables with a related allowance recorded 486 486 367 — Total installment receivables $ 1,512 $ 1,512 $ 367 $ — Installment receivables by class as of December 31, 2020 consist of the following (in thousands): Total Unpaid Related Interest U.S. Impaired installment receivables with a related allowance recorded $ 615 $ 615 $ 487 $ — Asia Pacific Non-impaired installment receivables with no related allowance recorded 1,194 1,194 — — Canada Non-impaired installment receivables with no related allowance recorded — — — 29 Total Non-impaired installment receivables with no related allowance recorded 1,194 1,194 — 29 Impaired installment receivables with a related allowance recorded 615 615 487 — Total installment receivables $ 1,809 $ 1,809 $ 487 $ 29
Schedule of Aging of Installment Receivables	The aging of the company’s installment receivables was as follows (in thousands): March 31, 2021 December 31, 2020 Total U.S. Asia Pacific Total U.S. Asia Pacific Current $ 1,026 $ — $ 1,026 $ 1,194 $ — $ 1,194 0-30 days past due — — — — — — 31-60 days past due — — — — — — 61-90 days past due — — — — — — 90+ days past due 486 486 — 615 615 — $ 1,512 $ 486 $ 1,026 $ 1,809 $ 615 $ 1,194

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consist of the following (in thousands): March 31, 2021 December 31, 2020 Finished goods $ 60,574 $ 55,264 Raw materials 57,855 51,174 Work in process 13,965 9,046 Inventories, net $ 132,394 $ 115,484

Other Current Assets (Tables)

Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Current Assets	Other current assets consist of the following (in thousands): March 31, 2021 December 31, 2020 Tax receivables principally value added taxes $ 17,697 $ 22,500 Receivable due from information technology provider 3,020 2,995 Prepaid insurance 2,746 3,963 Prepaid inventory 2,106 2,700 Recoverable income taxes 816 2,182 Derivatives (foreign currency forward exchange contracts) 723 1,321 Service contracts 573 633 Deferred financing fees 342 208 Prepaid and other current assets 7,460 8,215 Other Current Assets $ 35,483 $ 44,717

Other Long-Term Assets (Tables)

Other Long-Term Assets (Tables)	3 Months Ended
	Mar. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Assets, Noncurrent	Other long-term assets consist of the following (in thousands): March 31, 2021 December 31, 2020 Cash surrender value of life insurance policies $ 2,325 $ 2,327 Deferred income taxes 1,617 2,048 Installment receivables 906 943 Deferred financing fees 599 411 Investments 84 85 Other 112 111 Other Long-Term Assets $ 5,643 $ 5,925

Property And Equipment (Tables)

Property And Equipment (Tables)	3 Months Ended
	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property and equipment consist of the following (in thousands): March 31, 2021 December 31, 2020 Machinery and equipment $ 294,325 $ 294,045 Land, buildings and improvements 28,761 28,509 Capitalized software 20,514 17,527 Furniture and fixtures 9,957 10,001 Leasehold improvements 8,247 8,194 Property and Equipment, gross 361,804 358,276 Accumulated depreciation (304,011) (302,033) Property and Equipment, net $ 57,793 $ 56,243

Intangibles (Tables)

Intangibles (Tables)	3 Months Ended
	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Indefinite-Lived Intangible Assets	The company's intangibles consist of the following (in thousands): March 31, 2021 December 31, 2020 Historical Accumulated Historical Accumulated Customer lists $ 55,235 $ 55,235 $ 54,502 $ 54,502 Trademarks 25,509 — 25,112 — Developed technology 8,019 7,338 7,924 7,204 Patents 5,558 5,558 5,556 5,556 License agreements 2,909 1,042 2,899 979 Other 1,161 1,152 1,162 1,151 Intangibles $ 98,391 $ 70,325 $ 97,155 $ 69,392
Schedule of Finite-Lived Intangible Assets	The company's intangibles consist of the following (in thousands): March 31, 2021 December 31, 2020 Historical Accumulated Historical Accumulated Customer lists $ 55,235 $ 55,235 $ 54,502 $ 54,502 Trademarks 25,509 — 25,112 — Developed technology 8,019 7,338 7,924 7,204 Patents 5,558 5,558 5,556 5,556 License agreements 2,909 1,042 2,899 979 Other 1,161 1,152 1,162 1,151 Intangibles $ 98,391 $ 70,325 $ 97,155 $ 69,392

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2021
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consist of accruals for the following (in thousands): March 31, 2021 December 31, 2020 Salaries and wages $ 33,399 $ 34,029 Taxes other than income taxes, primarily value added taxes 24,705 32,710 Warranty 11,091 10,991 Professional 10,672 7,375 Interest 3,870 2,076 Freight 3,773 3,190 IT service contracts 3,582 3,799 Derivative liabilities (foreign currency forward exchange contracts) 3,399 1,432 Deferred revenue 3,112 3,516 Product liability, current portion 2,698 2,453 Rebates 2,553 8,644 Severance 865 6,249 Insurance 782 878 Rent 583 585 Supplemental Executive Retirement Program liability 391 391 Other items, principally trade accruals 6,803 7,955 Accrued Expenses $ 112,278 $ 126,273
Schedule of Product Warranty Liability	The following is a reconciliation of the changes in accrued warranty costs for the reporting period (in thousands): Balance as of January 1, 2021 $ 10,991 Warranties provided during the period 1,471 Settlements made during the period (1,477) Changes in liability for pre-existing warranties during the period, including expirations 106 Balance as of March 31, 2021 $ 11,091

Long-Term Debt (Tables)

Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	Debt consists of the following (in thousands): March 31, 2021 December 31, 2020 Convertible senior notes at 5.00%, due in February 2021 $ — $ 1,242 Convertible senior notes at 4.50%, due in June 2022 2,627 73,869 Convertible senior notes Series I at 5.00%, due in November 2024 71,939 62,984 Convertible senior notes Series II at 5.00%, due November 2024 75,334 64,919 Convertible senior notes at 4.25%, due in March 2026 117,786 — Other obligations 20,904 42,039 288,590 245,053 Less current maturities of long-term debt (4,840) (5,612) Long-Term Debt $ 283,750 $ 239,441
Liability Components of Convertible 2021 Note	The liability components of the 2021 Notes consist of the following (in thousands): March 31, 2021 December 31, 2020 Principal amount of liability component $ — $ 1,250 Unamortized discount — (7) Debt fees — (1) Net carrying amount of liability component $ — $ 1,242
Liability Components of Convertible 2022 Note	The liability components of the 2022 notes consist of the following (in thousands): March 31, 2021 December 31, 2020 Principal amount of liability component $ 2,650 $ 81,500 Unamortized discount — (6,772) Debt fees (23) (859) Net carrying amount of liability component $ 2,627 $ 73,869
Liability Components of Convertible 2024 Note	The liability components of the Series I 2024 Notes consist of the following (in thousands): March 31, 2021 December 31, 2020 Principal amount of liability component $ 72,909 $ 72,909 Unamortized discount — (8,888) Debt fees (970) (1,037) Net carrying amount of liability component $ 71,939 $ 62,984
Liability Components of Convertible Series II 2024 Note	The liability components of the Series II 2024 Notes consist of the following (in thousands): March 31, 2021 December 31, 2020 Principal amount of liability component - including accretion $ 76,558 $ 75,688 Unamortized discount — (9,461) Debt fees (1,224) (1,308) Net carrying amount of liability component $ 75,334 $ 64,919
Liability Components of Convertible 2026 Note	The liability components of the 2026 Notes consist of the following (in thousands): March 31, 2021 Principal amount of liability component $ 125,000 Debt fees (7,214) Net carrying amount of liability component $ 117,786

Other Long-Term Obligations (Ta

Other Long-Term Obligations (Tables)	3 Months Ended
	Mar. 31, 2021
Other Liabilities Disclosure [Abstract]
Other Noncurrent Liabilities	Other long-term obligations consist of the following (in thousands): March 31, 2021 December 31, 2020 Deferred income taxes $ 23,605 $ 23,234 Product liability 12,968 12,304 Pension 9,107 9,088 Deferred gain on sale leaseback 5,421 5,502 Supplemental Executive Retirement Plan liability 5,319 5,368 Deferred compensation 5,192 5,318 Uncertain tax obligation including interest 3,135 3,114 Other 6,525 6,546 Other Long-Term Obligations $ 71,272 $ 70,474

Leases and Commitments (Tables)

Leases and Commitments (Tables)	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Lease, Cost [Table]	Lease expenses for the three months ended March 31, 2021 and March 31, 2020, respectively, were as follows (in thousands): For the Three Months Ended March 31, 2021 2020 Operating leases $ 1,962 $ 2,243 Variable and short-term leases 1,051 921 Total operating leases $ 3,013 $ 3,164 Finance lease interest cost $ 1,178 $ 328 Finance lease depreciation 1,276 703 Total finance leases $ 2,454 $ 1,031
Schedule of Future Minimum Rental Payments for Operating Leases [Table]	Future minimum operating and finance lease commitments, as of March 31, 2021, are as follows (in thousands): Finance Operating Leases 2021 $ 6,714 $ 5,433 2022 7,051 4,225 2023 6,947 1,967 2024 6,878 1,360 2025 6,821 1,083 Thereafter 81,091 2,319 Total future minimum lease payments 115,502 16,387 Amounts representing interest (43,572) (2,421) Present value of minimum lease payments 71,930 13,966 Less: current maturities of lease obligations (3,584) (5,610) Long-term lease obligations $ 68,346 $ 8,356
Schedule of Future Minimum Lease Payments for Capital Leases [Table]	Future minimum operating and finance lease commitments, as of March 31, 2021, are as follows (in thousands): Finance Operating Leases 2021 $ 6,714 $ 5,433 2022 7,051 4,225 2023 6,947 1,967 2024 6,878 1,360 2025 6,821 1,083 Thereafter 81,091 2,319 Total future minimum lease payments 115,502 16,387 Amounts representing interest (43,572) (2,421) Present value of minimum lease payments 71,930 13,966 Less: current maturities of lease obligations (3,584) (5,610) Long-term lease obligations $ 68,346 $ 8,356
Schedule of Cash Flow, Supplemental Disclosures [Table]	Supplemental cash flow amounts for the three months ended March 31, 2021 were as follows (in thousands): Cash Activity: Cash paid in measurement of amounts for lease liabilities March 31, 2021 Operating leases $ 3,020 Finance leases 2,109 Total $ 5,129 Non-Cash Activity: Right-of-use assets obtained in exchange for lease obligations March 31, 2021 Operating leases $ 3,839 Finance leases 5,975 Total $ 9,814
Weighted-Average Remaining Lease Terms and Discount Rates [Table]	Weighted-average remaining lease terms and discount rates for finance and operating leases are as follows as of March 31, 2021: March 31, 2021 Weighted-average remaining lease term - finance leases 16.5 years Weighted-average remaining lease term - operating leases 4.7 years Weighted-average discount rate - finance leases 6.50% Weighted-average discount rate - operating leases 7.74%

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Mar. 31, 2021
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue Recognition, Multiple-deliverable Arrangements	The following tables disaggregate the company’s revenues by major source and by reportable segment for the three months ended March 31, 2021 and March 31, 2020 (in thousands): Three Months Ended March 31, 2021 Product Service Total Europe $ 109,844 $ 2,931 $ 112,775 North America 75,702 272 75,974 All Other 6,178 1,275 7,453 Total $ 191,724 $ 4,478 $ 196,202 % Split 98% 2% 100% Three Months Ended March 31, 2020 Product Service Total Europe $ 117,685 $ 3,283 $ 120,968 North America 86,764 207 86,971 All Other 9,322 1,179 10,501 Total $ 213,771 $ 4,669 $ 218,440 % Split 98% 2% 100%

Equity Compensation (Tables)

Equity Compensation (Tables)	3 Months Ended
	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan	The amounts of equity-based compensation expense recognized as part of SG&A expenses in All Other in business segment reporting were as follows (in thousands): For the Three Months Ended March 31, 2021 2020 Restricted stock / units $ 912 $ 775 Performance shares / units 668 425 Total stock-based compensation expense $ 1,580 $ 1,200
Schedule of Unrecognized Compensation Cost, Nonvested Awards	As of March 31, 2021, unrecognized compensation expense related to equity-based compensation arrangements granted under the company's 2018 Plan and previous plans, which is related to non-vested options and shares, was as follows (in thousands): March 31, 2021 Restricted stock and restricted stock units $ 11,733 Performance shares and performance share units 9,537 Total unrecognized stock-based compensation expense $ 21,270
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes information about stock option activity for the three months ended March 31, 2021: Weighted Average Options outstanding at January 1, 2021 1,081,804 $ 16.07 Forfeited (38,200) 17.01 Options outstanding at March 31, 2021 1,043,604 $ 16.03 Options exercise price range at March 31, 2021 $ 12.15 to $ 33.36 Options exercisable at March 31, 2021 1,043,604 Shares available for grant at March 31, 2021* 905,188 ________
Schedule of Share-based Compensation, Stock Options Outstanding	The following table summarizes information about stock options outstanding at March 31, 2021: Options Outstanding Options Exercisable Exercise Prices Number Weighted Average Weighted Average Number Weighted Average $12.15 – $20.00 750,159 4.7 $ 12.69 750,159 $ 12.69 $20.01 – $30.00 288,949 0.4 24.45 288,949 24.45 $30.01 – $33.36 4,496 0.1 33.36 4,496 33.36 Total 1,043,604 3.5 $ 16.03 1,043,604 $ 16.03
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	The following table summarizes information about restricted stock and restricted stock units (primarily for non-U.S. recipients): Weighted Average Fair Value Stock / Units unvested at 1,145,058 $ 8.62 Granted 617,707 8.48 Forfeited (8,190) 9.38 Stock / Units unvested at 1,754,575 $ 8.57
Share-based Compensation, Performance Shares Award Unvested Activity	The following table summarizes information about performance shares and performance share units (primarily for non-U.S. recipients): Weighted Average Fair Value Shares / Units unvested at January 1, 2021 1,026,785 $ 8.55 Granted 471,819 8.49 Shares / Units unvested at 1,498,604 $ 8.53

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) by Component (Tables)	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	Changes in accumulated other comprehensive income ("OCI") (in thousands): Foreign Currency Long-Term Notes Defined Benefit Plans Derivatives Total December 31, 2020 $ 50,329 $ (517) $ (3,674) $ (702) $ 45,436 OCI before reclassifications 2,802 2,875 470 (1,218) 4,929 Amount reclassified from accumulated OCI — — (121) 426 305 Net current-period OCI 2,802 2,875 349 (792) 5,234 March 31, 2021 $ 53,131 $ 2,358 $ (3,325) $ (1,494) $ 50,670 Foreign Currency Long-Term Notes Defined Benefit Plans Derivatives Total December 31, 2019 $ 8,898 $ (2,491) $ (3,299) $ 20 $ 3,128 OCI before reclassifications 1,664 (5,858) (598) (261) (5,053) Amount reclassified from accumulated OCI — — 429 119 548 Net current-period OCI 1,664 (5,858) (169) (142) (4,505) March 31, 2020 $ 10,562 $ (8,349) $ (3,468) $ (122) $ (1,377)
Schedule of Amounts Recognized in Other Comprehensive Income (Loss)	Reclassifications out of accumulated OCI were as follows (in thousands): Amount reclassified from OCI Affected line item in the Statement of Comprehensive (Income) Loss For the Three Months Ended March 31, 2021 2020 Defined Benefit Plans Service and interest costs $ (121) $ 429 Selling, general and administrative expenses Tax — — Income tax provision Total after tax $ (121) $ 429 Derivatives Foreign currency forward contracts hedging sales $ 22 $ 115 Net sales Foreign currency forward contracts hedging purchases 452 35 Cost of products sold Total loss before tax 474 150 Tax (48) (31) Income tax benefit Total after tax $ 426 $ 119

Charges Related To Restructur_2

Charges Related To Restructuring Activities (Tables)	3 Months Ended
	Mar. 31, 2021
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs	A progression by reporting segment of the accruals recorded as a result of the restructuring for the three months ended March 31, 2021 is as follows (in thousands): Severance Contract Terminations Total December 31, 2020 Balances North America $ 179 $ — $ 179 Europe 5,904 4 5,908 All Other 166 — 166 Total 6,249 4 6,253 Charges North America 822 — 822 Europe 454 276 730 All Other — — — Total 1,276 276 1,552 Payments North America (236) — (236) Europe (6,047) — (6,047) All Other — — — Total (6,283) — (6,283) March 31, 2021 Balances North America 765 — 765 Europe 311 280 591 All Other 166 — 166 Total $ 1,242 $ 280 $ 1,522

Net Earnings (Loss) Per Commo_2

Net Earnings (Loss) Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth the computation of basic and diluted net earnings (loss) per common share for the periods indicated. (In thousands except per share data) For the Three Months Ended March 31, 2021 2020 Basic Weighted average common shares outstanding 34,495 33,784 Net income (loss) $ (14,044) $ 732 Net income (loss) per common share $ (0.41) $ 0.02 Diluted Weighted average common shares outstanding 34,495 33,784 Share options and awards 715 69 Weighted average common shares assuming dilution 35,210 33,853 Net income (loss) $ (14,044) $ 732 Net income (loss) per common share * $ (0.41) $ 0.02 ________ * Net income (loss) per common share assuming dilution calculated utilizing weighted average shares outstanding-basic for the periods in which there was a net loss.

Derivatives (Tables)

Derivatives (Tables)	3 Months Ended
	Mar. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Notional Amounts of Outstanding Derivative Positions	Outstanding foreign currency forward exchange contracts qualifying and designated for hedge accounting treatment were as follows (in thousands USD): March 31, 2021 December 31, 2020 Notional Unrealized Notional Unrealized USD / CHF 1,240 (1) 1,675 (11) USD / EUR 44,156 (902) 56,187 (636) USD / GBP 1,892 (97) 2,467 (19) USD / SEK 2,009 (60) 2,658 (41) USD / MXN 2,492 258 2,230 334 EUR / CHF 3,847 56 5,037 10 EUR / GBP 14,796 (488) 19,060 44 EUR / SEK 7,586 (96) 10,162 (73) EUR / NOK 3,532 (116) 4,167 (64) AUD / NZD 614 (18) 781 (13) DKK / SEK 2,273 17 3,329 9 NOK / SEK 2,461 (66) 3,431 (50) AUD / THB 3,888 (260) 4,963 (221) NZD / THB 1,381 (55) 1,755 (55) USD / THB 3,114 89 4,152 (56) EUR / THB 1,034 12 1,332 18 GBP / THB 652 38 842 10 $ 96,967 $ (1,689) $ 124,228 $ (814)
Schedule of Other Derivatives Not Designated as Hedging Instruments, Statements of Financial Performance and Financial Position, Location	Foreign currency forward exchange contracts not qualifying or designated for hedge accounting treatment, as well as ineffective hedges, entered into in 2021 and 2020, respectively, and outstanding were as follows (in thousands USD): March 31, 2021 December 31, 2020 Notional Gain Notional Gain AUD / USD $ 5,776 $ 111 $ 6,046 $ (159) CAD / USD 13,086 (139) 8,320 88 DKK / USD 8,859 (320) 8,690 207 GBP / USD 16,947 (418) 16,062 338 NOK / USD 9,522 (175) 9,053 264 AUD / NZD 6,497 (46) 6,579 (35) $ 60,687 $ (987) $ 54,750 $ 703
Schedule of Derivatives Instruments Statements of Financial Position, Fair Value	The fair values of the company’s derivative instruments were as follows (in thousands): March 31, 2021 December 31, 2020 Assets Liabilities Assets Liabilities Derivatives designated as hedging instruments under ASC 815 Foreign currency forward exchange contracts $ 470 $ 2,159 $ 424 $ 1,238 Derivatives not designated as hedging instruments under ASC 815 Foreign currency forward exchange contracts 253 1,240 897 194 Total derivatives $ 723 $ 3,399 $ 1,321 $ 1,432
Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss)	The effect of derivative instruments on Accumulated Other Comprehensive Income (OCI) and the Condensed Statement of Comprehensive Income (Loss) was as follows (in thousands): Derivatives (foreign currency forward exchange contracts) in ASC 815 cash flow hedge Amount of Gain Amount of Gain (Loss) Amount of Gain (Loss) Three months ended March 31, 2021 Foreign currency forward exchange contracts $ (1,218) $ (426) $ — Three months ended March 31, 2020 Foreign currency forward exchange contracts $ (261) $ (119) $ 64 Derivatives (foreign currency forward exchange contracts) not designated as hedging Amount of Gain (Loss) Three months ended March 31, 2021 Foreign currency forward exchange contracts $ (987) Three months ended March 31, 2020 Foreign currency forward exchange contracts $ (724)

Fair Values (Tables)

Fair Values (Tables)	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table provides a summary of the company’s assets and liabilities that are measured on a recurring basis (in thousands): Basis for Fair Value Measurements at Reporting Date Quoted Prices in Active Significant Other Significant Other Level I Level II Level III March 31, 2021 Forward exchange contracts—net — $ (2,676) — December 31, 2020 Forward exchange contracts—net — $ (111) —
Fair Value, by Balance Sheet Grouping	The carrying values and fair values of the company’s financial instruments are as follows (in thousands): March 31, 2021 December 31, 2020 Carrying Value Fair Value Carrying Value Fair Value Cash and cash equivalents $ 86,052 $ 86,052 $ 105,298 $ 105,298 Other investments 84 84 85 85 Installment receivables, net of reserves 1,145 1,145 1,322 1,322 Forward contracts in Other Current Assets 723 723 1,321 1,321 Forward contracts in Accrued Expenses (3,399) (3,399) (1,432) (1,432) Total debt (including current maturities of long-term debt) * (288,590) (287,592) (245,053) (237,948) 2021 Notes — — (1,242) (1,264) 2022 Notes (2,627) (2,480) (73,869) (70,633) Series I 2024 Notes (71,939) (70,377) (62,984) (60,035) Series II 2024 Notes (75,334) (75,510) (64,919) (64,090) 2026 Notes (117,786) (118,874) — — Other (20,904) (20,351) (42,039) (41,926) ________ * The company's total debt is shown net of applicable discounts and fees associated with the convertible senior notes due in 2021, 2022, 2024 and 2026 on the company's condensed consolidated balance sheet. Accordingly, the fair values of the convertible senior notes due in 2021, 2022, 2024 and 2026 included in the long-term debt presented in this table are also shown net of the discounts and fees. Discount balances applicable to the company's convertible senior notes were eliminated upon adoption of ASU 2020-06 on January 1, 2021, but are included in the balances above for the period prior to adoption. Refer to Long-Term Debt footnote for discount balances by convertible senior notes series. Total debt excludes operating and finance leases obligations.

Business Segments (Tables)

Business Segments (Tables)	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The information by segment is as follows (in thousands): For the Three Months Ended March 31, 2021 2020 Revenues from external customers Europe $ 112,775 $ 120,968 North America 75,974 86,971 All Other (Asia Pacific) 7,453 10,501 Consolidated $ 196,202 $ 218,440 Intersegment revenues Europe $ 5,308 $ 4,226 North America 14,195 20,482 All Other (Asia Pacific) — 2,529 Consolidated $ 19,503 $ 27,237 Restructuring charges before income taxes Europe $ 730 $ 665 North America 822 691 All Other — 36 Consolidated $ 1,552 $ 1,392 Operating income (loss) Europe $ 3,832 $ 6,850 North America (2,375) (2,045) All Other (5,640) (3,555) Charge expense related to restructuring activities (1,552) (1,392) Gain on sale of business — 9,590 Consolidated operating income (loss) (5,735) 9,448 Loss on debt extinguishment including debt finance charges and associated fees (709) — Net interest expense (5,730) (6,616) Earnings (Loss) before income taxes $ (12,174) $ 2,832
Revenue from External Customer [Line Items]
Revenue from External Customers by Products and Services [Table Text Block]	Net sales by product, are as follows (in thousands): For the Three Months Ended March 31, 2021 2020 Europe Lifestyle $ 58,298 $ 58,303 Mobility and Seating 44,222 52,778 Respiratory Therapy 6,038 4,931 Other(1) 4,217 4,956 $ 112,775 $ 120,968 North America Lifestyle $ 36,185 $ 42,541 Mobility and Seating 22,733 29,574 Respiratory Therapy 16,784 14,649 Other(1) 272 207 $ 75,974 $ 86,971 All Other (Asia Pacific) Mobility and Seating $ 3,218 $ 5,435 Lifestyle 2,524 3,132 Respiratory Therapy 282 533 Other(1) 1,429 1,401 $ 7,453 $ 10,501 Total Consolidated $ 196,202 $ 218,440 ________________________ (1) Includes various services, including repair services, equipment rentals and external contracting.

Accounting Policies (Details)

Accounting Policies (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Accounting Policies [Abstract]
Adoption of ASU 2020-06, Convertible Debt Discounts Removed	$ 25,218,000
Debt Discount Amortization, per Basic and Diluted Share		$ 0.08
Convertible debt discount amortization and accretion	$ 870,000	$ 2,732,000

Divested Businesses (Details)

Divested Businesses (Details) - USD ($)	2 Months Ended	3 Months Ended		6 Months Ended	12 Months Ended
	Mar. 07, 2020	Mar. 31, 2021	Mar. 31, 2020	Jun. 30, 2020	Dec. 31, 2020
Divested Businesses [Abstract]
Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net	$ 4,129,000
Disposal Group, Including Discontinued Operation, Revenue	5,331,000			$ 30,261,000
Disposal Group, Including Discontinued Operation, Inter-Company Revenue	2,532,000			13,087,000
Disposal Group, Including Discontinued Operation, Earnings Before Taxes	445,000			$ 853,000
Proceeds from sale of business		$ 0	$ 14,563,000
Gain on sale of business		0	9,590,000		$ (9,790,000)
Disposal Group, Including Discontinued Operation, Inventory	3,082,000
Disposal Group, Including Discontinued Operation, Other Assets	855,000
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment	600,000
Disposal Group, Including Discontinued Operation, Operating Lease Right-of-Use Asset	2,127,000
Total Assets	10,793,000
Disposal Group, Including Discontinued Operation, Accounts Payable	4,692,000
Disposal Group, Including Discontinued Operation, Accrued Liabilities	2,473,000
Disposal Group, Including Discontinued Operation, Accrued Income Tax Payable	41,000
Disposal Group, Including Discontinued Operation, Operating Lease, Liability, Current	366,000
Disposal Group, Including Discontinued Operation, Operating Lease, Liability, NonCurrent	1,019,000
Disposal Group, Including Discontinued Operation, Liabilities	$ 8,591,000
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale of business		0	$ 9,590,000		$ (9,790,000)
Disposal Group, Including Discontinued Operation, Divestiture Accrual Balance		$ 240,000

Receivables (Narrative) (Detail

Receivables (Narrative) (Details)	3 Months Ended
	Mar. 31, 2021USD ($)payment
Accounts, Notes, Loans and Financing Receivable [Line Items]
Contingent Liability, Guarantee	$ 407,000
Number of missed payments before delinquent | payment	3
Credit amount requiring additional analysis	$ 250,000
Average period of adjudication	18 months
Financing Receivables Not Past 90 Days Due	90 days
Risk Level, Low
Accounts, Notes, Loans and Financing Receivable [Line Items]
Receivables, Expected Loss Percentage, North America excluding Canada	1.00%
Receivables, Expected Loss Percentage, Canada	0.20%
Receivables, Expected Loss Percentage, Europe	0.40%
Receivables, Expected Loss Percentage, AsiaPac	0.30%
Risk Level, Medium
Accounts, Notes, Loans and Financing Receivable [Line Items]
Receivables, Expected Loss Percentage, Canada	1.50%
Risk Level, High
Accounts, Notes, Loans and Financing Receivable [Line Items]
Receivables, Expected Loss Percentage, Canada	2.50%

Receivables (Schedule of Accoun

Receivables (Schedule of Accounts Receivable) (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Schedule of Accounts Receivable [Abstract]
Accounts receivable, gross	$ 118,278	$ 131,055
Customer rebate reserve	(8,914)	(10,730)
Cash discount reserves	(4,995)	(7,320)
Allowance for doubtful accounts	(4,172)	(4,031)
Other, principally returns and allowances reserves	(424)	(386)
Accounts Receivable, Net	$ 99,773	$ 108,588

Receivables Schedule for Allowa

Receivables Schedule for Allowance for Credit Losses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Financing Receivable, Allowance for Credit Losses [Line Items]
Allowance for Credit Losses	$ 4,172	$ 4,031
Allowance for Loan and Lease Losses, Adjustments, Other	131
Financing Receivable, Allowance for Credit Losses, Write-downs	$ 10

Receivables (Installment Receva

Receivables (Installment Recevables) (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Receivables [Abstract]
Non-Impaired Financing Receivable, Related Allowance	$ 0	$ 0
Installment Receivables, Current	455,000	704,000
Installment Receivables, Long-Term	1,057,000	1,105,000
Total Installment Receivables	1,512,000	1,809,000
Total Unearned Interest	(3,112,000)	(3,516,000)
Allowance for doubtful accounts, current	(216,000)	(325,000)
Allowance for doubtful accounts, long-term	(151,000)	(162,000)
Allowance for doubtful accounts	(367,000)	(487,000)	$ (1,514,000)
Installment receivables, net	239,000	379,000
Installment receivables, net, long-term	906,000	943,000
Installment receivables, net	$ 1,145,000	$ 1,322,000

Receivables (Rollforward of All

Receivables (Rollforward of Allowance for Doubtful Accounts) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Allowance for Doubtful Accounts [Roll Forward]
Balance as of beginning of period	$ 487	$ 1,514
Current period provision (benefit)	(86)	66
Direct write-offs charged against the allowance	(34)	(1,093)
Balance as of end of period	$ 367	$ 487

Receivables (Installment Receiv

Receivables (Installment Receivables by Class) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Total Installment Receivables
Non-Impaired installment receivables with no related allowance recorded	$ 1,026	$ 1,194
Impaired installment receivables with a related allowance recorded	486	615
Total installment receivables	1,512	1,809
Unpaid Principal Balance
Impaired installment receivables with a related allowance recorded	486	615
Non-Impaired installment receivables with no related allowance recorded	1,026	1,194
Total installment receivables	1,512	1,809
Non-Impaired Financing Receivable, Related Allowance	0	0
Related Allowance for Doubtful Accounts
Impaired Financing Receivable, Related Allowance	367	487
Interest Income Recognized
Non-Impaired installment receivables with no related allowance recorded	0	29
Impaired Financing Receivable, with Related Allowance, Interest Income, Accrual Method	0	0
Total installment receivables	0	29
All Other
Total Installment Receivables
Non-Impaired installment receivables with no related allowance recorded	1,026	1,194
Unpaid Principal Balance
Non-Impaired installment receivables with no related allowance recorded	1,026	1,194
Non-Impaired Financing Receivable, Related Allowance	0	0
Interest Income Recognized
Non-Impaired installment receivables with no related allowance recorded	0	0
North America (NA)
Total Installment Receivables
Impaired installment receivables with a related allowance recorded	486	615
Unpaid Principal Balance
Impaired installment receivables with a related allowance recorded	486	615
Related Allowance for Doubtful Accounts
Impaired Financing Receivable, Related Allowance	367	487
Interest Income Recognized
Impaired Financing Receivable, with Related Allowance, Interest Income, Accrual Method	$ 0	0
IVC Canada
Total Installment Receivables
Non-Impaired installment receivables with no related allowance recorded		0
Unpaid Principal Balance
Non-Impaired installment receivables with no related allowance recorded		0
Non-Impaired Financing Receivable, Related Allowance		0
Interest Income Recognized
Non-Impaired installment receivables with no related allowance recorded		$ 29

Receivables (Aging of Installme

Receivables (Aging of Installment Receivables) (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Financing Receivable, Recorded Investment, Past Due [Line Items]
0-30 days past due	$ 0	$ 0
31-60 days past due	0	0
61-90 days past due	0	0
90+ days past due	486	615
Installment Receivable, Not Past Due	1,026	1,194
Financing Receivable, Gross	1,512	1,809
All Other
Financing Receivable, Recorded Investment, Past Due [Line Items]
0-30 days past due	0	0
31-60 days past due	0	0
61-90 days past due	0	0
90+ days past due	0	0
Installment Receivable, Not Past Due	1,026	1,194
Financing Receivable, Gross	1,026	1,194
North America (NA)
Financing Receivable, Recorded Investment, Past Due [Line Items]
0-30 days past due	0	0
31-60 days past due	0	0
61-90 days past due	0	0
90+ days past due	486	615
Installment Receivable, Not Past Due	0	0
Financing Receivable, Gross	$ 486	$ 615

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Finished goods	$ 60,574	$ 55,264
Raw materials	57,855	51,174
Work in process	13,965	9,046
Inventory, net	$ 132,394	$ 115,484

Other Current Assets Components

Other Current Assets Components of Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Tax receivables principally value added taxes	$ 17,697	$ 22,500
Receivable due from information technology provider	3,020	2,995
Prepaid insurance	2,746	3,963
Prepaid inventory	2,106	2,700
Recoverable income taxes	816	2,182
Derivatives (foreign currency forward exchange contracts)	723	1,321
Service contracts	573	633
Deferred financing fees	342	208
Prepaid and other current assets	7,460	8,215
Other current assets	$ 35,483	$ 44,717

Other Long-Term Assets Componen

Other Long-Term Assets Components of Other Long-Term Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Cash surrender value of life insurance policies	$ 2,325	$ 2,327
Deferred income taxes	1,617	2,048
Installment receivables	906	943
Deferred financing fees	599	411
Investments	84	85
Other	112	111
Other Long-Term Assets	$ 5,643	$ 5,925

Property And Equipment (Details

Property And Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 361,804	$ 358,276
Less allowance for depreciation	(304,011)	(302,033)
Property and equipment, net	57,793	56,243
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	294,325	294,045
Land, buildings and improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	28,761	28,509
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	9,957	10,001
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	8,247	8,194
Capitalized Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 20,514	$ 17,527

Intangibles (Narrative) (Detail

Intangibles (Narrative) (Details)	3 Months Ended
	Mar. 31, 2021USD ($)
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 102,000
Minimum
Finite-Lived Intangible Assets [Line Items]
Finite-Lived intangible assets, useful life	4 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Finite-Lived intangible assets, useful life	9 years
Weighted Average
Finite-Lived Intangible Assets [Line Items]
Finite-Lived intangible assets, useful life	7 years

Intangibles (Intangible Table)

Intangibles (Intangible Table) (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	$ 98,391	$ 97,155
Accumulated Amortization	70,325	69,392
Customer lists
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	55,235	54,502
Accumulated Amortization	55,235	54,502
Developed technology
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	8,019	7,924
Accumulated Amortization	7,338	7,204
Patents
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	5,558	5,556
Accumulated Amortization	5,558	5,556
License agreements
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	2,909	2,899
Accumulated Amortization	1,042	979
Other
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	1,161	1,162
Accumulated Amortization	1,152	1,151
Trademarks
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	$ 25,509	$ 25,112

Intangibles (Finite-Lived Intan

Intangibles (Finite-Lived Intangible Asset Future Amortization Expense) (Details)	Mar. 31, 2021USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Future amortization expense, remainder of fiscal year	$ 409,000
Future amortization expense, 2022	410,000
Future amortization expense, 2023	410,000
Future amortization expense, 2024	354,000
Future amortization expense, 2025	213,000
Future amortization expense, 2026	$ 211,000

Accrued Expenses Components of

Accrued Expenses Components of Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Salaries and wages	$ 33,399	$ 34,029
Taxes other than income taxes, primarily value added taxes	24,705	32,710
Warranty	11,091	10,991
Professional	10,672	7,375
Interest	3,870	2,076
Freight	3,773	3,190
IT service contracts	3,582	3,799
Derivative liabilities (foreign currency forward exchange contracts)	3,399	1,432
Deferred revenue	3,112	3,516
Product liability, current portion	2,698	2,453
Rebates	2,553	8,644
Severance	865	6,249
Insurance	782	878
Rent	583	585
Supplemental Executive Retirement Program liability	391	391
Other items, principally trade accruals	6,803	7,955
Accrued expenses	$ 112,278	$ 126,273

Accrued Expenses Warranty Sched

Accrued Expenses Warranty Schedule (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Product Liability Contingency
Balance as of January 1, 2021	$ 10,991
Warranties provided during the period	1,471
Settlements made during the period	(1,477)
Changes in liability for pre-existing warranties during the period, including expirations	106
Balance as of March 31, 2021	$ 11,091

Long-Term Debt (Details)

Long-Term Debt (Details)	3 Months Ended					12 Months Ended
	Mar. 31, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2020USD ($)	Sep. 30, 2019USD ($)	Jun. 30, 2017USD ($)	Dec. 31, 2016USD ($)	Mar. 31, 2016USD ($)
Debt Instrument [Line Items]
Long-term debt	$ 288,590,000						$ 245,053,000
Long-term Debt and Capital Lease Obligations, Current	(4,840,000)						(5,612,000)
Long-term debt net of current maturities	283,750,000						239,441,000
Accretion Expense	$ 870,000
Accretion Rate	4.70%
Gain (Loss) on Repurchase of Debt Instrument						$ 280,000
Loss on debt extinguishment including debt finance charges and fees	$ (709,000)	$ 761,000		$ 0
Purchases of capped calls	$ 18,787,000			0
Cap Price of Capped Call Transaction | $ / shares	$ 16.58
Lifetime to date - Accretion Expense	$ 2,683,000
Remaining Accretion	$ 13,939,000
CARES Act Loan [Member]
Debt Instrument [Line Items]
Interest rate (as a percent)	1.00%
Convertible Subordinated Debt
Debt Instrument [Line Items]
Debt and Capital Leases Disclosures	Long-Term Debt Debt consists of the following (in thousands): March 31, 2021 December 31, 2020 Convertible senior notes at 5.00%, due in February 2021 $ — $ 1,242 Convertible senior notes at 4.50%, due in June 2022 2,627 73,869 Convertible senior notes Series I at 5.00%, due in November 2024 71,939 62,984 Convertible senior notes Series II at 5.00%, due November 2024 75,334 64,919 Convertible senior notes at 4.25%, due in March 2026 117,786 — Other obligations 20,904 42,039 288,590 245,053 Less current maturities of long-term debt (4,840) (5,612) Long-Term Debt $ 283,750 $ 239,441 On September 30, 2015, the company entered into an Amended and Restated Revolving Credit and Security Agreement, which was subsequently amended (the “Credit Agreement”) and which matures on January 16, 2024. The Credit Agreement was entered into by and among the company, certain of the company’s direct and indirect U.S. and Canadian subsidiaries and certain of the company’s European subsidiaries (together with the company, the “Borrowers”), certain other of the company’s direct and indirect U.S., Canadian and European subsidiaries (the “Guarantors”), and PNC Bank, National Association (“PNC”), JPMorgan Chase Bank, N.A., J.P. Morgan Europe Limited, KeyBank National Association, and Citizens Bank, National Association (the “Lenders”). PNC is the administrative agent (the “Administrative Agent”) and J.P. Morgan Europe Limited is the European agent (the “European Agent”) under the Credit Agreement. In connection with entering into the company's Credit Agreement, the company incurred fees which were capitalized and are being amortized as interest expense. As of March 31, 2021, debt fees yet to be amortized through January 2024 totaled $941,000. The company had outstanding letters of credit of $8,301,000 and $7,752,000 as of March 31, 2021 and December 31, 2020, respectively. Outstanding letters of credit and other reserves impacting borrowing capacity were $7,570,000 and $7,616,000 as of March 31, 2021 and December 31, 2020, respectively. The company had no outstanding borrowings under its North America Credit Facility as of March 31, 2021. The company had outstanding borrowings of $5,916,000 (€4,900,000) under its French Credit Facility and $4,460,000 (£3,200,000) under its UK Credit Facility as of March 31, 2021, together referred to as the European Credit Facility. The company had outstanding borrowings of $20,000,000 under its North America Credit Facility as of December 31, 2020. The company had outstanding borrowings of $7,636,000 (€6,400,000) under its French Credit Facility and $3,866,000 (£2,900,000) under its UK Credit Facility as of December 31, 2020, together referred to as the European Credit Facility. The weighted average interest rate on all borrowings, excluding finance leases, was 4.5% for the three months ended March 31, 2021 and 4.6% for the year ended December 31, 2020. North America Borrowers Credit Facility For the company's North America Borrowers, the Credit Agreement provides for an asset-based-lending senior secured revolving credit facility which is secured by substantially all the company’s U.S. and Canadian assets, other than real estate. The Credit Agreement provides the company and the other Borrowers with a credit facility in an aggregate principal amount of $60,000,000, subject to availability based on a borrowing base formula, under a senior secured revolving credit, letter of credit and swing line loan facility (the “North America Credit Facility”). Up to $20,000,000 of the North America Credit Facility will be available for issuance of letters of credit. The aggregate principal amount of the North America Credit Facility may be increased by up to $25,000,000 to the extent requested by the company and agreed to by any Lender or new financial institution approved by the Administrative Agent. The aggregate borrowing availability under the North America Credit Facility is determined based on a borrowing base formula. The aggregate usage under the North America Credit Facility may not exceed an amount equal to the sum of (a) 85% of eligible U.S. accounts receivable plus (b) the lesser of (i) 70% of eligible U.S. inventory and eligible foreign in-transit inventory and (ii) 85% of the net orderly liquidation value of eligible U.S. inventory and eligible foreign in-transit inventory (not to exceed $4,000,000), plus (c) the lesser of (i) 80% of the net orderly liquidation value of U.S. eligible machinery and equipment and (ii) $0 as of March 31, 2021 (subject to reduction as provided in the Credit Agreement), plus (d) 85% of eligible Canadian accounts receivable, plus (e) the lesser of (i) 70% of eligible Canadian inventory and (ii) 85% of the net orderly liquidation value of eligible Canadian inventory, less (f) swing loans outstanding under the North America Credit Facility, less (g) letters of credit issued and undrawn under the North America Credit Facility, less (h) a $3,000,000 minimum availability reserve, less (i) other reserves required by the Administrative Agent, and in each case subject to the definitions and limitations in the Credit Agreement. As of March 31, 2021, the company was in compliance with all covenant requirements. As of March 31, 2021, the company had gross borrowing base of $38,389,000 and net borrowing availability of $21,070,000 under the North America Credit Facility under the Credit Agreement, considering the minimum availability reserve, then-outstanding letters of credit, other reserves and the $6,750,000 dominion trigger amount described below. Borrowings under the North America Credit Facility are secured by substantially all of the company’s U.S. and Canadian assets, other than real estate. Interest will accrue on outstanding indebtedness under the Credit Agreement at the LIBOR rate, plus a margin ranging from 2.25% to 2.75%, or at the alternate base rate, plus a margin ranging from 1.25% to 1.75%, as selected by the company. Borrowings under the North America Credit Facility are subject to commitment fees of 0.25% or 0.375% per year, depending on utilization. The Credit Agreement contains customary representations, warranties and covenants. Exceptions to the operating covenants in the Credit Agreement provide the company with flexibility to, among other things, enter into or undertake certain sale and leaseback transactions, dispositions of assets, additional credit facilities, sales of receivables, additional indebtedness and intercompany indebtedness, all subject to limitations set forth in the Credit Agreement, as amended. The Credit Agreement also contains a covenant requiring the company to maintain minimum availability under the North America Credit Facility of not less than (i) 12.5% of the maximum amount that may be drawn under the North America Credit Facility for five (5) consecutive business days, or (ii) 11.25% of the maximum amount that may be drawn under the North American facility on any business day. The company also is subject to dominion triggers under the North America Credit Facility requiring the company to maintain borrowing capacity of not less than $6,750,000 on any business day or any five consecutive days in order to avoid triggering full control by an agent for the Lenders of the company's cash receipts for application to the company’s obligations under the agreement. The Credit Agreement contains customary default provisions, with certain grace periods and exceptions, which provide for events of default that include, among other things, failure to pay amounts due, breach of covenants, representations or warranties, bankruptcy, the occurrence of a material adverse effect, exclusion from any medical reimbursement program, and an interruption of any material manufacturing facilities for more than 10 consecutive days. The proceeds of the North America Credit Facility will be used to finance the working capital and other business needs of the company. There was $0 outstanding borrowings under the North America Credit Facility at March 31, 2021. European Credit Facility The Credit Agreement also provides for a revolving credit, letter of credit and swing line loan facility which gives the company and the European Borrowers the ability to borrow up to an aggregate principal amount of $30,000,000, with a $5,000,000 sublimit for letters of credit and a $2,000,000 sublimit for swing line loans (the “European Credit Facility”). Up to $15,000,000 of the European Credit Facility will be available to each of Invacare Limited (the “UK Borrower”) and Invacare Poirier SAS (the “French Borrower” and, together with the UK Borrower, the “European Borrowers”). The European Credit Facility matures in January 2024, together with the U.S. and Canadian Credit Facility. The aggregate borrowing availability for each European Borrower under the European Credit Facility is determined based on a borrowing base formula. The aggregate borrowings of each of the European Borrowers under the European Credit Facility may not exceed an amount equal to (a) 85% of the European Borrower’s eligible accounts receivable, less (b) the European Borrower’s borrowings and swing line loans outstanding under the European Credit Facility, less (c) the European Borrower’s letters of credit issued and undrawn under the European Credit Facility, less (d) a $3,000,000 minimum availability reserve, less (e) other reserves required by the European Agent, and in each case subject to the definitions and limitations in the Credit Agreement. As of March 31, 2021, the gross borrowing base to the European Borrowers under the European Credit Facility was $17,098,000 and the net borrowing availability was $10,722,000, considering the $3,000,000 minimum availability reserve and a $3,375,000 dominion trigger amount described below. Borrowing availability is based on a prior month base in USD. Actual borrowings in GBP and EUR fluctuate in USD between date of borrowing and when translated for consolidated reporting. The aggregate principal amount of the European Credit Facility may be increased by up to $10,000,000 to the extent requested by the company and agreed to by any Lender or Lenders that wish to increase their lending participation or, if not agreed to by any Lender, a new financial institution that agrees to join the European Credit Facility and that is approved by the Administrative Agent and the European Agent. Interest will accrue on outstanding indebtedness under the European Credit Facility at the LIBOR rate, plus a margin ranging from 2.50% to 3.00%, or for swing line loans, at the overnight LIBOR rate, plus a margin ranging from 2.50% to 3.00%, as selected by the company. The margin that will be adjusted quarterly based on utilization. Borrowings under the European Credit Facility are subject to commitment fees of 0.25% or 0.375% per year, depending on utilization. The European Credit Facility is secured by substantially all the personal property assets of the UK Borrower and its in-country subsidiaries, and all the receivables of the French Borrower and its in-country subsidiaries. The UK and French facilities (which comprise the European Credit Facility) are cross collateralized, and the US personal property assets previously pledged under the U.S. and Canadian Credit Facility also serve as collateral for the European Credit Facility. The European Credit Facility is subject to customary representations, warranties and covenants generally consistent with those applicable to the U.S. and Canadian Credit Facility. Exceptions to the operating covenants in the Credit Agreement provide the company with flexibility to, among other things, enter into or undertake certain sale/leaseback transactions, dispositions of assets, additional credit facilities, sales of receivables, additional indebtedness and intercompany indebtedness, all subject to limitations set forth in the Credit Agreement. The Credit Agreement also contains a covenant requiring the European Borrowers to maintain undrawn availability under the European Credit Facility of not less than (i) 12.5% of the maximum amount that may be drawn under the European Credit Facility for five (5) consecutive business days, or (ii) 11.25% of the maximum amount that may be drawn under the European credit facility on any business day. The European Borrowers also are subject to cash dominion triggers under the European Credit Facility requiring the European Borrower to maintain borrowing capacity of not less than $3,750,000 on any business day or $3,375,000 for five consecutive business days in order to avoid triggering full control by an agent for the Lenders of the European Borrower’s cash receipts for application to its obligations under the European Credit Facility. The European Credit Facility is subject to customary default provisions, with certain grace periods and exceptions, consistent with those applicable to the U.S. and Canadian Credit Facility, which provide that events of default include, among other things, failure to pay amounts due, breach of covenants, representations or warranties, cross-default, bankruptcy, the occurrence of a material adverse effect, exclusion from any medical reimbursement program, and an interruption in the operations of any material manufacturing facility for more than 10 consecutive days. The proceeds of the European Credit Facility will be used to finance the working capital and other business needs of the company. As of March 31, 2021, the company had borrowings of $5,916,000 (€4,900,000) under its French Credit Facility and $4,460,000 (£3,200,000) under its UK Credit Facility as of March 31, 2021, together referred to as the European Credit Facility. In January 2021, the Credit Agreement was amended to provide for, among other things, the addition of the company's Netherlands subsidiary as a guarantor under the European revolving credit facility, amendments to the restrictive covenants in the Credit Agreement to (1) increase the maximum amount of permitted miscellaneous indebtedness to $30,000,000 from $10,000,000 and (2) permit up to $9,000,000 of financing based on certain European public and government receivables, and terms that, upon the occurrence of certain events related to a transition from the use of LIBOR, permit the agent for the lenders to amend the Credit Agreement to replace the LIBOR rate and/or the Euro rate with a benchmark replacement rate. In March 2021, the Credit Agreement was further amended to permit the issuance of the 2026 Notes and the capped call transactions entered into by the company in connection with the issuance of the 2026 Notes, as further discussed in the sections below. Convertible senior notes due 2021 In the first quarter of 2016, the company issued $150,000,000 aggregate principal amount of 5.00% Convertible Senior Notes due 2021 (the “2021 Notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The 2021 Notes bore interest at a rate of 5.00% per year payable semi-annually in arrears on February 15 and August 15 of each year, beginning August 15, 2016. The 2021 Notes matured on February 15, 2021. At maturity, $1,250,000 principal amount of 2021 Notes were outstanding, which the company repaid in cash. In connection with the offering of the 2021 Notes, the company entered into privately negotiated convertible note hedge transactions with two financial institutions (the “option counterparties”). The company evaluated the note hedges under the applicable accounting literature, including Derivatives and Hedging , ASC 815, and determined that the note hedges should be accounted for as derivatives. These derivatives were capitalized on the balance sheet as long-term assets and adjusted to reflect fair value each quarter. The fair value of the convertible note hedge assets at issuance was $27,975,000. The company entered into separate, privately negotiated warrant transactions with the option counterparties at a higher strike price relating to the same number of the company’s common shares, subject to customary anti-dilution adjustments, pursuant to which the company sold warrants to the option counterparties. The warrants could have a dilutive effect on the company’s outstanding common shares and the company’s earnings per share to the extent that the price of the company’s common shares exceeds the strike price of those warrants. The initial strike price of the warrants is $22.4175 per share and is subject to certain adjustments under the terms of the warrant transactions. The company evaluated the warrants under the applicable accounting literature, including Derivatives and Hedging , ASC 815, and determined that the warrants met the definition of a derivative, are indexed to the company's own stock and should be classified in shareholder's equity. The amount paid for the warrants and capitalized in shareholder's equity was $12,376,000. The net proceeds from the offering of the 2021 Notes were approximately $144,034,000, after deducting fees and offering expenses of $5,966,000, which were paid in 2016. These debt issuance costs were capitalized and were amortized as interest expense through February 2021. Debt issuance costs are presented on the balance sheet as a direct deduction from the carrying amount of the related debt liability. During the third quarter of 2019, the company used an aggregate of $14,708,000 in cash to repurchase a total amount of $16,000,000 in principal amount of 2021 Notes. After recognizing expenses on unamortized fees and discounts associated with the repurchased 2021 Notes, the repurchases resulted in a net reduction of debt of $14,367,000 and a net loss on the repurchases of $280,000. During the fourth quarter of 2019, the company entered into separate privately negotiated agreements with certain holders of its 2021 Notes to exchange $72,909,000 in aggregate principal amount of 2021 Notes for aggregate consideration of $72,909,000 in aggregate principal amount of new 5.00% Convertible Senior Exchange Notes due 2024 (the “Series I 2024 Notes”) of the company and $6,928,000 in cash. Refer to "Convertible senior notes Series I due 2024" below for more information. As a result of the exchange transaction in the fourth quarter of 2019 and the repurchase of $16,000,000 in principal amount of 2021 Notes in the third quarter of 2019, a partial unwind of the note hedge options and warrants entered into with the issuance of the 2021 Notes also occurred during the fourth quarter of 2019. Note hedge options outstanding related to the 2021 Notes were reduced from the original number of 300,000 to 138,182 and warrants relating to the 2021 Notes were reduced from the initial number of 9,007,380 to 3,860,624. The partial unwind of the note hedge options and warrants resulted in no net impact to cash or paid in capital. During the second quarter of 2020, the company entered into separate, privately negotiated agreements with certain holders of its 2021 Notes and certain holders of its 2022 Notes to exchange $35,375,000 in aggregate principal amount of 2021 Notes and $38,500,000 in aggregate principal amount of 2022 notes, for aggregate consideration of $73,875,000 in aggregate principal amount of new 5.00% Series II Convertible Senior Exchange Notes due 2024 (the “Series II 2024 Notes”) of the company and $5,593,000 in cash. During the third quarter of 2020, the company repurchased $24,466,000 aggregate principal amount of 2021 Notes, resulting in a $761,000 loss on debt extinguishment. As a result of the repurchase of 2021 Notes in the third quarter of 2020 and the exchange of 2021 Notes for new notes in the second quarter of 2020, a partial unwind of the note hedge options and warrants entered into with the issuance of the 2021 Notes also occurred. The partial unwind of the note hedge options and warrants resulted in no net impact to cash or paid-in-capital. Note hedge options outstanding relating to the 2021 Notes were reduced 62,341 and subsequently expired on February 15, 2021. Warrants outstanding on March 31, 2021 were 3,141,943. If exercised, one Common Share is issuable upon exercise of each warrant, but may be adjusted to include additional Common Shares for each warrant under certain circumstances if the relevant share price exceeds the warrant strike price for the relevant measurement period at the time of exercise. Common Shares are reserved for issuance upon exercise of the remaining warrants relating to the 2021 Notes at two Common Shares per warrant. The warrants will begin to expire on May 15, 2021 and then partially expire on each trading day over the 220 trading day period following May 15, 2021. The liability components of the 2021 Notes consist of the following (in thousands): March 31, 2021 December 31, 2020 Principal amount of liability component $ — $ 1,250 Unamortized discount — (7) Debt fees — (1) Net carrying amount of liability component $ — $ 1,242 The unamortized discount was reduced to $0 upon adoption of ASU 2020-06, effective January 1, 2021. The effective interest rate on the liability component was 11.1% upon original issuance including consideration of the discount. Non-cash discount interest expense of $824,000 was recognized for the three months ended March 31, 2020. Interest expense of $8,000 was accrued for the three months ended March 31, 2021, compared to $745,000 for the three months ended March 31, 2020 based on the stated coupon rate of 5.0%. Convertible senior notes due 2022 In the second quarter of 2017, the company issued $120,000,000 aggregate principal amount of 4.50% Convertible Senior Notes due 2022 (the “2022 Notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The 2022 Notes bear interest at a rate of 4.50% per year payable semi-annually in arrears on June 1 and December 1 of each year, beginning December 1, 2017. The 2022 Notes will mature on June 1, 2022, unless repurchased or converted in accordance with their terms prior to such date. Prior to December 1, 2021, the 2022 Notes will be convertible only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. Prior to May 16, 2019, the 2022 Notes were convertible, subject to certain conditions, into cash only. On May 16, 2019, the company obtained shareholder approval under applicable New York Stock Exchange rules such that conversion of the 2022 Notes may be settled in cash, the company’s common shares or a combination of cash and the company’s common shares, at the company’s election. At March 31, 2021, $2,650,000 aggregate principal amount of the 2022 Notes remained outstanding, following the exchange transactions completed in the second quarter of 2020 and the repurchase of debt completed in the first quarter of 2021, as further discussed below. Holders of the 2022 Notes may convert their 2022 Notes at their option at any time prior to the close of business on the business day immediately preceding December 1, 2021 only under the following circumstances: (1) during any fiscal quarter commencing after September 30, 2017 (and only during such fiscal quarter), if the last reported sale price of the company’s common shares for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the applicable conversion price for the 2022 Notes on each applicable trading day; (2) during the five “trading price” (as defined in the Indenture) per one thousand U.S. dollar principal amount of 2022 Notes for each trading day of such measurement period was less than 98% of the product of the last reported sale price of the company’s Common Shares and the applicable conversion rate for the 2022 Notes on each such trading day; or (3) upon the occurrence of specified corporate events described in the Indenture. On or after December 1, 2021 until the close of business on the second scheduled trading day immediately preceding the maturity of the 2022 Notes, holders may convert their 2022 Notes, at the option of the holder, regardless of the foregoing circumstances. Holders of the 2022 Notes will have the right to require the company to repurchase all or some of their 2022 Notes at 100% of their principal, plus any accrued and unpaid interest, upon the occurrence of certain fundamental changes. The initial conversion rate is 61.6095 common shares per $1,000 principal amount of 2022 Notes (equivalent to an initial conversion price of approximately $16.23 per common share). Until the company received shareholder approval on May 16, 2019 authorizing it to elect to settle future conversions of the 2022 Notes in common shares, the company separately accounted for the conversion features as a derivative. The derivative was capitalized on the balance sheet as a long-term liability with adjustment to reflect fair value each quarter until the change to the conversion features as a result of the shareholder approval received on May 16, 2019 resulted in the termination of the derivative. The fair value of the convertible debt conversion liability at issuance was $28,859,000. The company recognized a loss of $6,193,000 in 2019 related to the convertible debt conversion liability. In connection with the offering of the 2022 Notes, the company entered into privately negotiated convertible note hedge transactions with one financial institution (the “option counterparty”). These transactions cover, subject to customary anti-dilution adjustments, the number of the company’s common shares that will initially underlie the 2022 Notes, and are expected generally to reduce the potential equity dilution, and/or offset any cash payments in excess of the principal amount due, as the case may be, upon conversion of the 2022 Notes. The company evaluated the note hedges under the applicable accounting literature, including Derivatives and Hedging , ASC 815, and determined that the note hedges should be accounted for as derivatives. These derivatives were capitalized on the balance sheet as long-term assets and will be adjusted to reflect fair value each quarter. The fair value of the convertible note hedge assets at issuance was $24,780,000. The company entered into separate, privately negotiated warrant transactions with the option counterparty at a higher strike price relating to the same number of the company’s common shares, subject to customary anti-dilution adjustments, pursuant to which the company sold warrants to the option counterparties. The warrants could have a dilutive effect on the company’s outstanding common shares and the company’s earnings per share to the extent that the price of the company’s common shares exceeds the strike price of those warrants. The initial strike price of the warrants is $21.4375 per share and is subject to certain adjustments under the terms of the warrant transactions. The company evaluated the warrants under the applicable accounting literature, including Derivatives and Hedging , ASC 815, and determined that the warrants meet the definition of a derivative, are indexed to the company's own shares and should be classified in shareholder's equity. The amount paid for the warrants and capitalized in shareholder's equity was $14,100,000. There were 120,000 note hedge options relating to the 2022 Notes outstanding at March 31, 2021, but only 2,650 remained available for exercise. Note hedge options related to the 2022 Notes will expire on June 1, 2022. Warrants relating to the 2022 Notes outstanding on March 31, 2021 were 7,393,141. If exercised, one Common Share is issuance upon exercise of each warrant, but may be adjusted under certain circumstances if the relevant share price exceeds the warrant strike price for the relevant share price exceeds the warrant strike price for the relevant measurement period at the time of exercise. Common Shares are reserved for issuance upon exercise of the remaining warrants relating to the 2022 Notes at two Common Shares per warrant. The warrants will begin to expire on September 1, 2022 and then partially expire on each trading day over the 220 trading day period following September 1, 2022. The net proceeds from the offering of the 2022 Notes were approximately $115,289,000, after deducting fees and offering expenses of $4,711,000, which were paid in 2017. These debt issuance costs were capitalized and are being amortized as interest expense through June 2022. Debt issuance costs are presented on the balance sheet as a direct deduction from the carrying amount of the related debt liability. A portion of the net proceeds from the offering were used to pay the cost of the convertible note hedge transactions (after such cost is partially offset by the proceeds to the company from the warrant transactions), which net cost was $10,680,000. During the second quarter of 2020, the company entered into separate, privately negotiated agreements with certain holders of its 2021 Notes and certain holders of its 2022 Notes to exchange $35,375,000 in aggregate principal amount of 2021 Notes and $38,500,000 in aggregate principal amount of 2022 Notes, for aggregate consideration of $73,875,000 in aggregate principal amount of new Series II 2024 Notes and $5,593,000 in cash. During the first quarter of 2021, the company repurchased $78,850,000 in principal amount of 2022 Notes, resulting in a loss on debt extinguishment of $709,000. The liability components of the 2022 notes consist of the following (in thousands): March 31, 2021 December 31, 2020 Principal amount of liability component $ 2,650 $ 81,500 Unamortized discount — (6,772) Debt fees (23) (859) Net carrying amount of liability component $ 2,627 $ 73,869 The unamortized discount was reduced to $0 upon adoption of ASU 2020-06, effective January 1, 2021. The effective interest rate on the liability component was 10.9% upon original issuance including consideration of the discount. Total interest expense subsequent to adoption of ASU 2020-06 includes coupon interest and amortization of debt fees. Non-cash discount interest expense of $1,460,000 was recognized for the three months ended March 31, 2020. Interest expense of $769,000 was accrued for the three months ended March 31, 2021 compared to $1,350,000 for the three months ended March 31, 2020 based on the stated coupon rate of 4.5%. The effective interest rate of the 2022 Notes as of March 31, 2021 was 5.2%. The 2022 Notes were not convertible as of March 31, 2021 nor was the applicable conversion threshold met. Convertible senior notes Series I due 2024 During the fourth quarter of 2019, the company entered into separate privately negotiated agreements with certain holders of its 2021 Notes to exchange $72,909,000 in aggregate principal amount of 2021 Notes for aggregate consideration of $72,909,000 in aggregate principal amount of new 5.00% Convertible Senior Exchange Notes due 2024 (the “Series I 2024 Notes”) of the company and $6,928,000 in cash. The notes bear interest at a rate of 5.00% per year payable semi-annually in arrears on May 15 and November 15 of each year, beginning May 15, 2020. The notes will mature on November 15, 2024, unless repurchased, redeemed or converted in accordance with their terms prior to such date. Prior to May 15, 2024, the Series I 2024 Notes will be convertible only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. The Series 2024 Notes may be settled in cash, the company’s common shares or a combination of cash and the company’s common shares, at the company’s election. Prior to the maturity of the Series I 2024 Notes, the company may, at its election, redeem for cash all or part of the Series I 2024 Notes if the last reported sale price of the company’s common shares equals or exceeds 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the company provides notice of redemption. The redemption price will be equal to 100% of the principal amount of the Series I 2024 Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date (subject to certain limited exceptions). No sinking fund is provided for t
Convertible Subordinated Debt | Convertible Senior Notes at 5.00% February 2021
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 0						1,250,000				$ 150,000,000
Long-term debt	0						1,242,000
Debt Instrument, Unamortized Discount	0						(7,000)
Debt Instrument, Fee Amount	0						(1,000)
Debt Instrument, Net Carrying Amount	$ 0						1,242,000
Interest rate (as a percent)	5.00%
Debt Instrument Repurchase Amount, Cash Paid								$ 14,708,000
Debt Instrument, Repurchase Amount		$ 24,466,000						16,000,000
Debt Instrurment Repurchase Amount, Net Reduction of debt								$ 14,367,000
Debt Instrument Exchange Amount			$ 35,375,000		$ 72,909,000
Debt Instrument, Hedge Options		62,341			138,182	138,182					300,000
Debt Instrument, Warrants Issued and Outstanding		3,141,943			3,860,624	3,860,624					9,007,380
Debt Instrument, Increase, Accrued Interest	$ 8,000			745,000
Debt Instrument, Fee Amount										$ 5,966,000
Debt Instrument, Interest Rate, Effective Percentage	11.10%
Debt Instrument, Non-Cash Interest Expense Recognized in the Period				824,000
Convertible Subordinated Debt | Convertible Senior Notes at 4.50% February 2022 [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 2,650,000						81,500,000		$ 120,000,000
Long-term debt	2,627,000						73,869,000
Debt Instrument, Unamortized Discount	0						(6,772,000)
Debt Instrument, Fee Amount	(23,000)						(859,000)
Debt Instrument, Net Carrying Amount	$ 2,627,000						73,869,000
Interest rate (as a percent)	4.50%
Debt Instrument Exchange Amount			38,500,000
Debt Instrument, Hedge Options	120,000
Debt Instrument, Increase, Accrued Interest	$ 769,000			1,350,000
Percent of the Applicable Conversion Price	130.00%
Last Reported Sales Price Period, Common Stock	20 days
Debt Instrument, Convertible, Threshold Consecutive Trading Days	30
Convertible Senior Notes, Percentage of Principal Required for Repurchase	100.00%
Convertible Debt, Conversion Rate of Commmon Shares, Principal	$ 1,000
Business Day Period	5 years
Debt Instrument, Convertible, Threshold Trading Days	10
Percent of the Product of the Last Reported Sale Price, Common Shares	98.00%
Convertible Preferred Stock, Shares Issued upon Conversion | shares	61.6095
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 16.23
Debt Instrument, Fee Amount									$ 4,711,000
Class of Warrant or Right, Outstanding | shares	7,393,141
Debt Instrument, Hedge Options available for exercise	2,650
Debt Instrument, Interest Rate, Effective Percentage	5.20%
Debt Instrument, Interest Rate on Liability Component, Effective Percentage	10.90%
Debt Instrument, Non-Cash Interest Expense Recognized in the Period				1,460,000
Convertible Subordinated Debt | Convertible Senior Notes at 5.00% November 2024 [Domain]
Debt Instrument [Line Items]
Long-term debt	$ 71,939,000						62,984,000
Debt Instrument, Convertible, Threshold Trading Days	10
Convertible Subordinated Debt | Series II Convertible Senior Notes at 5.00% November 2024 [Domain]
Debt Instrument [Line Items]
Long-term debt	$ 75,334,000						64,919,000
Business Day Period	5 years
Convertible Subordinated Debt | Convertible Senior Notes at 4.25% March 2026 [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 125,000,000
Long-term debt	$ 117,786,000						0
Interest rate (as a percent)	4.25%
Convertible Subordinated Debt | Convertible Senior Notes at 5.00% November 2024
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 72,909,000						72,909,000
Debt Instrument, Unamortized Discount	0						(8,888,000)
Debt Instrument, Fee Amount	(970,000)						(1,037,000)
Debt Instrument, Net Carrying Amount	$ 71,939,000						62,984,000
Interest rate (as a percent)	5.00%
Debt Instrument Repurchase Amount, Cash Paid					$ 6,928,000	$ 6,928,000
Debt Instrument, Increase, Accrued Interest	$ 911,000			911,000
Percent of the Applicable Conversion Price	130.00%
Last Reported Sales Price Period, Common Stock	20 days
Debt Instrument, Convertible, Threshold Consecutive Trading Days	30
Convertible Senior Notes, Percentage of Principal Required for Repurchase	100.00%
Convertible Debt, Conversion Rate of Commmon Shares, Principal	$ 1,000
Business Day Period	5 years
Percent of the Product of the Last Reported Sale Price, Common Shares	98.00%
Convertible Preferred Stock, Shares Issued upon Conversion | shares	67.6819
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 14.78
Debt Instrument, Loss on Exchange					5,885,000
Debt Instrument, Fee Amount					$ 1,394,000	$ 1,394,000
Debt Instrument, Interest Rate, Effective Percentage	540.00%
Debt Instrument, Interest Rate on Liability Component, Effective Percentage	8.77%
Debt Instrument, Non-Cash Interest Expense Recognized in the Period				$ 448,000
Convertible Subordinated Debt | Series II Convertible Senior Notes at 5.00% November 2024
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 76,558,000						75,688,000
Debt Instrument, Unamortized Discount	0						(9,461,000)
Debt Instrument, Fee Amount	(1,224,000)						(1,308,000)
Debt Instrument, Net Carrying Amount	$ 75,334,000						64,919,000
Interest rate (as a percent)	5.00%
Debt Instrument Repurchase Amount, Cash Paid							5,593,000
Debt Instrument Exchange Amount			73,875,000
Debt Instrument, Increase, Accrued Interest	$ 923,000
Percent of the Applicable Conversion Price	130.00%
Last Reported Sales Price Period, Common Stock	20 days
Debt Instrument, Convertible, Threshold Consecutive Trading Days	30
Convertible Senior Notes, Percentage of Principal Required for Repurchase	100.00%
Convertible Debt, Conversion Rate of Commmon Shares, Principal	$ 1,000
Debt Instrument, Convertible, Threshold Trading Days	10
Percent of the Product of the Last Reported Sale Price, Common Shares	98.00%
Convertible Preferred Stock, Shares Issued upon Conversion | shares	67.6819
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 14.78
Debt Instrument, Loss on Exchange	$ 709,000		$ 6,599,000
Debt Instrument, Fee Amount							1,505,000
Debt Instrument, Interest Rate, Effective Percentage	10.60%
Debt Instrument, Interest Rate on Liability Component, Effective Percentage	8.99%
Debt Instrument, Non-Cash Interest Expense Recognized in the Period	$ 870,000
Convertible Subordinated Debt | Convertible Senior Notes at 4.25% March 2026
Debt Instrument [Line Items]
Debt Instrument, Face Amount	125,000,000
Debt Instrument, Fee Amount	(7,214,000)
Debt Instrument, Net Carrying Amount	$ 117,786,000
Interest rate (as a percent)	4.25%
Debt Instrument, Increase, Accrued Interest	$ 236,000
Percent of the Applicable Conversion Price	130.00%
Last Reported Sales Price Period, Common Stock	20 days
Debt Instrument, Convertible, Threshold Consecutive Trading Days	30
Convertible Senior Notes, Percentage of Principal Required for Repurchase	100.00%
Convertible Debt, Conversion Rate of Commmon Shares, Principal	$ 1,000
Business Day Period	5 days
Debt Instrument, Convertible, Threshold Trading Days	10
Percent of the Product of the Last Reported Sale Price, Common Shares	98.00%
Convertible Preferred Stock, Shares Issued upon Conversion | shares	94.6096
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 10.57
Capped Call Options, Outstanding	125,000
Debt Instrument, Interest Rate, Effective Percentage	5.40%
Convertible Subordinated Debt | Convertible Senior Notes at 4.50% February 2022
Debt Instrument [Line Items]
Debt Instrument, Repurchase Amount	$ 78,850,000
Other Notes and Capital Lease Obligations
Debt Instrument [Line Items]
Long-term debt	20,904,000						42,039,000
Senior secured revolving credit facility, due in October 2015 | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement)
Debt Instrument [Line Items]
Line of Credit Facility, Fair Value of Amount Outstanding	0						20,000,000
Line of Credit Facility, Covenant Feature, Dominion Trigger	6,750,000
Line of Credit Facility, Foreign Currency Fair Value of Amount Outstanding (France)	5,916,000						7,636,000
Line of Credit Facility, Foreign Currency Fair Value of Amount Outstanding (UK)	4,460,000						3,866,000
Line Of Credit Facility Gross Borrowing Base	$ 38,389,000
Minimum required undrawn balance (as a percent)	11.25%
Senior secured revolving credit facility, due in October 2015 | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement) | Euro Member Countries, Euro
Debt Instrument [Line Items]
Line of Credit Facility, Foreign Currency Fair Value of Amount Outstanding (France)	$ 4,900,000						6,400,000
Senior secured revolving credit facility, due in October 2015 | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement) | United Kingdom, Pounds
Debt Instrument [Line Items]
Line of Credit Facility, Foreign Currency Fair Value of Amount Outstanding (UK)	3,200,000						$ 2,900,000
Senior secured revolving credit facility, due in October 2015 | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Line of Credit Facility, Covenant Feature, Dominion Trigger	3,750,000
Line Of Credit Facility Gross Borrowing Base	$ 17,098,000
Minimum required undrawn balance (as a percent)	12.50%
Remaining borrowing capacity	$ 30,000,000
Line of Credit Facility, Covenant Feature, Prior Limit	10,000,000
Line of Credit Facility, Covenant Feature, Increase Limit Based on receivables	9,000,000
Line of Credit Facility, Covenant Feature Dominion Trigger for Five Consecutive Days	$ 3,375,000
Senior secured revolving credit facility, due in October 2015 | Line of Credit | Revolving Credit and Security Agreement (North America Credit Agreement)
Debt Instrument [Line Items]
Minimum required undrawn balance (as a percent)	12.50%

Long-Term Debt Components of Co

Long-Term Debt Components of Convertible Debt (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2019	Jun. 30, 2017	Mar. 31, 2016	Dec. 31, 2020
Debt Instrument [Line Items]
Issuance of warrants					$ 12,376,000
Long-term debt	$ 288,590,000					$ 245,053,000
Convertible Subordinated Debt | Convertible Senior Notes at 5.00% February 2021
Debt Instrument [Line Items]
Debt Instrument, Increase, Accrued Interest	8,000	$ 745,000
Debt Instrument, Face Amount	$ 0				$ 150,000,000	1,250,000
Interest rate (as a percent)	5.00%
Unamortized discount	$ 0					(7,000)
Long-term debt	0					1,242,000
Debt fees	0					(1,000)
Debt Instrument, Net Carrying Amount	0					1,242,000
Convertible Subordinated Debt | Convertible Senior Notes at 4.50% February 2022 [Domain]
Debt Instrument [Line Items]
Debt Instrument, Increase, Accrued Interest	769,000	1,350,000
Debt Instrument, Face Amount	$ 2,650,000			$ 120,000,000		81,500,000
Issuance of warrants				$ 14,100,000
Interest rate (as a percent)	4.50%
Unamortized discount	$ 0					(6,772,000)
Long-term debt	2,627,000					73,869,000
Debt fees	(23,000)					(859,000)
Debt Instrument, Net Carrying Amount	2,627,000					73,869,000
Convertible Subordinated Debt | Convertible Senior Notes at 5.00% November 2024 [Domain]
Debt Instrument [Line Items]
Long-term debt	71,939,000					62,984,000
Convertible Subordinated Debt | Convertible Senior Notes at 5.00% November 2024
Debt Instrument [Line Items]
Debt Instrument, Increase, Accrued Interest	911,000	$ 911,000
Debt Instrument, Loss on Exchange			$ 5,885,000
Debt Instrument, Face Amount	$ 72,909,000					72,909,000
Interest rate (as a percent)	5.00%
Unamortized discount	$ 0					(8,888,000)
Debt fees	(970,000)					(1,037,000)
Debt Instrument, Net Carrying Amount	$ 71,939,000					$ 62,984,000

Long-Term Debt Narrative (Detai

Long-Term Debt Narrative (Details) - USD ($)	3 Months Ended							12 Months Ended
	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Jun. 30, 2017	Mar. 31, 2016	Dec. 31, 2019	Dec. 31, 2020	May 15, 2020	Sep. 30, 2019	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Issuance of warrants							$ 12,376,000
Payments for Repurchase of Common Stock	$ 0			$ 773,000
Amortization of debt fees	418,000			475,000
Loss on debt extinguishment including debt finance charges and fees	$ 709,000	$ (761,000)		0
CARES Act Loan [Member]
Debt Instrument [Line Items]
Interest rate (as a percent)	1.00%
Unsecured Debt										$ 10,000,000
Unsecured Debt, Current	$ 4,461,000
Convertible Subordinated Debt | Convertible Senior Notes at 5.00% November 2024 [Domain]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Threshold Trading Days	10
Convertible Subordinated Debt | Convertible Senior Notes at 5.00% November 2024
Debt Instrument [Line Items]
Debt Instrument, Fee Amount					$ 1,394,000			$ 1,394,000
Debt Instrument, Face Amount	$ 72,909,000								$ 72,909,000
Interest rate (as a percent)	5.00%
Debt Instrument Repurchase Amount, Cash Paid					6,928,000			6,928,000
Last Reported Sales Price Period, Common Stock	20 days
Debt Instrument, Convertible, Threshold Consecutive Trading Days	30
Percent of the Applicable Conversion Price	130.00%
Business Day Period	5 years
Percent of the Product of the Last Reported Sale Price, Common Shares	98.00%
Convertible Senior Notes, Percentage of Principal Required for Repurchase	100.00%
Convertible Preferred Stock, Shares Issued upon Conversion	67.6819
Convertible Debt, Conversion Rate of Commmon Shares, Principal	$ 1,000
Debt Instrument, Convertible, Conversion Price	$ 14.78
Debt Instrument, Net Carrying Amount	$ 71,939,000								62,984,000
Debt Instrument, Fee Amount	(970,000)								(1,037,000)
Debt Instrument, Unamortized Discount	$ 0								(8,888,000)
Debt Instrument, Interest Rate, Effective Percentage	540.00%
Debt Instrument, Non-Cash Interest Expense Recognized in the Period				448,000
Debt Instrument, Increase, Accrued Interest	$ 911,000			911,000
Debt Instrument, Loss on Exchange					5,885,000
Convertible Subordinated Debt | Convertible Senior Notes at 5.00% February 2021
Debt Instrument [Line Items]
Debt Instrument, Fee Amount													$ 5,966,000
Debt Instrument, Face Amount	$ 0						$ 150,000,000		1,250,000
Interest rate (as a percent)	5.00%
Debt Instrument Exchange Amount			$ 35,375,000		$ 72,909,000
Debt Instrument Repurchase Amount, Cash Paid											$ 14,708,000
Debt Instrument, Repurchase Amount		$ 24,466,000									$ 16,000,000
Convertible due 2021 - Bond Hedge, Fair Value at Issuance	$ 27,975,000
Derivative, Price Risk Option Strike Price	$ 22.4175
Debt Instrument, Net Proceeds													$ 144,034,000
Debt Instrument, Net Carrying Amount	$ 0								1,242,000
Debt Instrument, Fee Amount	0								(1,000)
Debt Instrument, Unamortized Discount	$ 0								(7,000)
Debt Instrument, Interest Rate, Effective Percentage	11.10%
Debt Instrument, Non-Cash Interest Expense Recognized in the Period				824,000
Debt Instrument, Increase, Accrued Interest	$ 8,000			745,000
Convertible Subordinated Debt | Convertible Senior Notes at 4.50% February 2022 [Domain]
Debt Instrument [Line Items]
Debt Instrument, Fee Amount						$ 4,711,000
Debt Instrument, Face Amount	$ 2,650,000					$ 120,000,000			81,500,000
Interest rate (as a percent)	4.50%
Debt Instrument Exchange Amount			38,500,000
Last Reported Sales Price Period, Common Stock	20 days
Debt Instrument, Convertible, Threshold Consecutive Trading Days	30
Percent of the Applicable Conversion Price	130.00%
Business Day Period	5 years
Debt Instrument, Convertible, Threshold Trading Days	10
Percent of the Product of the Last Reported Sale Price, Common Shares	98.00%
Convertible Senior Notes, Percentage of Principal Required for Repurchase	100.00%
Convertible Preferred Stock, Shares Issued upon Conversion	61.6095
Convertible Debt, Conversion Rate of Commmon Shares, Principal	$ 1,000
Debt Instrument, Convertible, Conversion Price	$ 16.23
Convertible Debt Conversion Feature, Fair Value at Issuance												$ 28,859,000
Convertible Debt Conversion Feature Gain (Loss)								$ 6,193,000
Convertible due 2022 - Bond Hedge, Fair Value at Issuance												$ 24,780,000
Derivative, Price Risk Option Strike Price						$ 21.4375
Issuance of warrants						$ 14,100,000
Debt Instrument, Net Proceeds						115,289,000
Debt Instrument, Net Carrying Amount	$ 2,627,000								73,869,000
Debt Instrument, Fee Amount	(23,000)								(859,000)
Derivative, Amount of Hedged Item						$ (10,680,000)
Debt Instrument, Unamortized Discount	$ 0								(6,772,000)
Debt Instrument, Interest Rate, Effective Percentage	5.20%
Debt Instrument, Non-Cash Interest Expense Recognized in the Period				1,460,000
Debt Instrument, Increase, Accrued Interest	$ 769,000			$ 1,350,000
Convertible Subordinated Debt | Convertible Senior Subordinated Debentures at 5.00% February 2021 [Domain]
Debt Instrument [Line Items]
Unamortized Financing Costs	941,000
Convertible Subordinated Debt | Series II Convertible Senior Notes at 5.00% November 2024
Debt Instrument [Line Items]
Debt Instrument, Fee Amount									1,505,000
Debt Instrument, Face Amount	$ 76,558,000								75,688,000
Interest rate (as a percent)	5.00%
Debt Instrument Exchange Amount			73,875,000
Debt Instrument Repurchase Amount, Cash Paid									5,593,000
Last Reported Sales Price Period, Common Stock	20 days
Debt Instrument, Convertible, Threshold Consecutive Trading Days	30
Percent of the Applicable Conversion Price	130.00%
Debt Instrument, Convertible, Threshold Trading Days	10
Percent of the Product of the Last Reported Sale Price, Common Shares	98.00%
Convertible Senior Notes, Percentage of Principal Required for Repurchase	100.00%
Convertible Preferred Stock, Shares Issued upon Conversion	67.6819
Convertible Debt, Conversion Rate of Commmon Shares, Principal	$ 1,000
Debt Instrument, Convertible, Conversion Price	$ 14.78
Debt Instrument, Net Carrying Amount	$ 75,334,000								64,919,000
Debt Instrument, Fee Amount	(1,224,000)								(1,308,000)
Debt Instrument, Unamortized Discount	$ 0								$ (9,461,000)
Debt Instrument, Interest Rate, Effective Percentage	10.60%
Debt Instrument, Non-Cash Interest Expense Recognized in the Period	$ 870,000
Debt Instrument, Increase, Accrued Interest	923,000
Debt Instrument, Loss on Exchange	$ 709,000		$ 6,599,000
Convertible Subordinated Debt | Series II Convertible Senior Notes at 5.00% November 2024 [Domain]
Debt Instrument [Line Items]
Business Day Period	5 years
Revolving Credit Facility | Line of Credit
Debt Instrument [Line Items]
Weighted average interest rate (as a percent)	4.50%								4.60%
Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Borrowing capacity	$ 30,000,000
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Trade Receivables, Europe, Percent	85.00%
Minimum availability reserve	$ 3,000,000
Line of Credit Facility, Covenant Feature, Dominion Trigger	3,750,000
Line of Credit Facility, Remaining Borrowing Capacity	10,722,000
Remaining borrowing capacity	$ 30,000,000
Minimum required undrawn balance (as a percent)	12.50%
Consecutive business days for minimum undrawn balance	5 days
Interruption of material manufacturing facilities, period	10 days
Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement)
Debt Instrument [Line Items]
Line of Credit Facility, Fair Value of Amount Outstanding	$ 0								$ 20,000,000
Borrowing capacity	60,000,000
Additional increase in borrowing capacity available	$ 25,000,000
Percentage of domestic accounts receivable	85.00%
Percentage of eligible domestic inventory and in-transit inventory	70.00%
Percentage of net orderly liquidation value of domestic inventory	85.00%
Maximum value of net orderly liquidation value domestic inventory and in-transit inventory	$ 4,000,000
Net orderly liquidation value of domestic eligible machinery and equipment	80.00%
Additional amount of machinery and equipment	$ 0
Percentage of eligible Canadian accounts receivable	85.00%
Percentage of eligible Canadian inventory	70.00%
Percentage of net orderly liquidation value of eligible Canadian inventory	85.00%
Minimum availability reserve	$ 3,000,000
Line of Credit Facility, Current Borrowing Capacity	21,070,000
Line of Credit Facility, Covenant Feature, Dominion Trigger	$ 6,750,000
Minimum required undrawn balance (as a percent)	11.25%
Line of Credit, Covenant Compliance, Consecutive Business Days for Undrawn_Balance	5 days
Interruption of material manufacturing facilities, period	10 days
Line of Credit Facility, Foreign Currency Fair Value of Amount Outstanding (France)	$ 5,916,000								7,636,000
Line of Credit Facility, Foreign Currency Fair Value of Amount Outstanding (UK)	4,460,000								3,866,000
Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement) | Euro Member Countries, Euro
Debt Instrument [Line Items]
Line of Credit Facility, Foreign Currency Fair Value of Amount Outstanding (France)	4,900,000								6,400,000
Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement) | United Kingdom, Pounds
Debt Instrument [Line Items]
Line of Credit Facility, Foreign Currency Fair Value of Amount Outstanding (UK)	3,200,000								2,900,000
Letter of Credit
Debt Instrument [Line Items]
Line of Credit Facility, Fair Value of Amount Outstanding	7,570,000								7,616,000
Letters of Credit Outstanding, Amount	8,301,000								$ 7,752,000
Letter of Credit | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Borrowing capacity	5,000,000
Letter of Credit | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement)
Debt Instrument [Line Items]
Borrowing capacity	20,000,000
Swing Line Loans | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Borrowing capacity	2,000,000
Amount Available to Invacare Limited and Invacare Poirier SAS | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Borrowing capacity	$ 15,000,000
Minimum | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Commitment fee percentage	0.25%
Minimum | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement)
Debt Instrument [Line Items]
Commitment fee percentage	0.25%
Minimum | London Interbank Offered Rate (LIBOR) | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Basis spread on variable rate	2.50%
Minimum | London Interbank Offered Rate (LIBOR) | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement)
Debt Instrument [Line Items]
Basis spread on variable rate	2.25%
Minimum | Base Rate | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Basis spread on variable rate	2.50%
Minimum | Base Rate | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement)
Debt Instrument [Line Items]
Basis spread on variable rate	1.25%
Maximum | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Commitment fee percentage	0.375%
Maximum | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement)
Debt Instrument [Line Items]
Commitment fee percentage	0.375%
Maximum | London Interbank Offered Rate (LIBOR) | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Basis spread on variable rate	3.00%
Maximum | London Interbank Offered Rate (LIBOR) | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement)
Debt Instrument [Line Items]
Basis spread on variable rate	2.75%
Maximum | Base Rate | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Basis spread on variable rate	3.00%
Maximum | Base Rate | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement)
Debt Instrument [Line Items]
Basis spread on variable rate	1.75%

Long-Term Debt Sale Leaseback T

Long-Term Debt Sale Leaseback Transactions (Details)	Apr. 23, 2015USD ($)
Sale Leaseback Transaction [Line Items]
Sale Leaseback Transaction, Deferred Gain, Gross	$ 7,414,000

Other Long-Term Obligations (De

Other Long-Term Obligations (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Apr. 23, 2015
Other Liabilities Disclosure [Abstract]
Deferred income taxes	$ 23,605,000		$ 23,234,000
Product liability	12,968,000		12,304,000
Pension	9,107,000		9,088,000
Deferred gain on sale leaseback	5,421,000		5,502,000
Supplemental Executive Retirement Plan liability	5,319,000		5,368,000
Deferred compensation	5,192,000		5,318,000
Uncertain tax obligation including interest	3,135,000		3,114,000
Other	6,525,000		6,546,000
Other Long-Term Obligations	71,272,000		$ 70,474,000
Sale Leaseback Transaction, Deferred Gain, Gross				$ 7,414,000
Sale Leaseback Transaction, Current Period Gain Recognized	$ 78,000	$ 75,000

Leases and Commitments (Details

Leases and Commitments (Details) - USD ($)	Apr. 23, 2015	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2015	Dec. 01, 2020	Jul. 01, 2020
Lessee, Lease, Description [Line Items]
Finance Lease, Liability					$ 5,561,000	$ 36,916,000
Sale Leaseback Transaction, Net Proceeds, Investing Activities				$ 23,000,000
Sale Leaseback Transaction, Annual Rental Payments		$ 2,275,000
Sale Leaseback Transaction, Lease Terms		Each of the four lease agreements contains three 10-year renewals with the rent for each option term based on the greater of the then-current fair market rent for each property or the then- current rate and increasing annually by the applicable CPI. Under the terms of the lease agreements, the company is responsible for all taxes, insurance and utilities. The company is required to adequately maintain each of the properties and any leasehold improvements will be amortized over the lesser of the lives of the improvements or the remaining lease lives, consistent with any other company leases.
Sale Leaseback Transaction, Deferred Gain, Gross	$ 7,414,000
Sale Leaseback Transaction, Immediate Loss Recognized	257,000
Capital Lease Obligations	$ 32,339,000
Sale Leaseback Transaction, Current Period Gain Recognized		$ 78,000	$ 75,000
20 Years
Lessee, Lease, Description [Line Items]
Lessee, Finance Lease, Term of Contract		20 years
12.6 Years
Lessee, Lease, Description [Line Items]
Lessee, Finance Lease, Term of Contract		12 years 7 months 6 days
Minimum
Lessee, Lease, Description [Line Items]
General Lease Term		1 year
Maximum
Lessee, Lease, Description [Line Items]
General Lease Term		20 years

Leases and Commitments Lease Ex

Leases and Commitments Lease Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Leases [Abstract]
Operating Lease, Expense	$ 1,962	$ 2,243
Short-term Lease, Cost	1,051	921
Operating Lease, Cost	3,013	3,164
Finance Lease, Interest Expense	1,178	328
Finance Lease, Right-of-Use Asset, Amortization	1,276	703
Financing Lease, Cost	$ 2,454	$ 1,031

Leases and Commitments Future M

Leases and Commitments Future Minimum Operating and Financing Lease Commitments (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Finance Lease, Liability, Payments, Due Next Twelve Months	$ 6,714
Operating Leases, Future Minimum Payments Due, Next Twelve Months	5,433
Finance Lease, Liability, Payments, Due Year Two	7,051
Operating Leases, Future Minimum Payments, Due in Two Years	4,225
Finance Lease, Liability, Payments, Due Year Three	6,947
Operating Leases, Future Minimum Payments, Due in Three Years	1,967
Finance Lease, Liability, Payments, Due Year Four	6,878
Operating Leases, Future Minimum Payments, Due in Four Years	1,360
Finance Lease, Liability, Payments, Due Year Five	6,821
Operating Leases, Future Minimum Payments, Due in Five Years	1,083
Finance Lease, Liability, Payments, Due after Year Five	81,091
Operating Leases, Future Minimum Payments, Due Thereafter	2,319
Finance Lease, Liability, Payments, Due	115,502
Operating Leases, Future Minimum Payments Due	16,387
Financing Leases, Future Minimum Payments, Interest Included in Payments	(43,572)
Operating Leases, Future Minimum Payments, Interest Included in Payments	(2,421)
Financing Leases, Future Minimum Payments, Present Value of Net Minimum Payments	71,930
Operating Leases, Future Minimum Payments, Present Value of Net Minimum Payments	13,966
Finance Lease, Liability, Current	(3,584)	$ (3,405)
Operating Lease, Liability, Current	(5,610)	(6,313)
Financing Lease Liability, non-current	68,346
Operating Leases Long-Term Obligations	$ 8,356	$ 8,697

Leases and Commitments Suppleme

Leases and Commitments Supplemental Cash Flow Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Leases [Abstract]
Operating Leases, Cash Paid in Measurement of Amounts for Lease Liabilities	$ 3,020
Financing Leases, Cash Paid in Measurement of Amounts for Lease Liabilities	2,109
Total Cash Paid in Measurement of Amounts for Lease Liabilities	5,129
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	3,839
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability	5,975
Right-of-Use Asset Obtained in Exchange for Total Lease Liability	$ 9,814

Leases and Commitments Weighted

Leases and Commitments Weighted-Average Remaining Lease Terms and Discount Rates (Details)	Mar. 31, 2021
Leases [Abstract]
Finance Lease, Weighted Average Remaining Lease Term	16 years 6 months
Operating Lease, Weighted Average Remaining Lease Term	4 years 8 months 12 days
Finance Lease, Weighted Average Discount Rate, Percent	6.50%
Operating Lease, Weighted Average Discount Rate, Percent	7.74%

Revenue (Details)

Revenue (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	$ 196,202,000	$ 218,440,000
Net Revenue	100.00%	100.00%
Deferred Revenue	$ 3,112,000		$ 3,516,000
Product
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	$ 191,724,000	$ 213,771,000
Net Revenue	98.00%	98.00%
Service
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	$ 4,478,000	$ 4,669,000
Net Revenue	2.00%	2.00%
Europe (EMEA)
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	$ 112,775,000	$ 120,968,000
Europe (EMEA) | Product
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	109,844,000	117,685,000
Europe (EMEA) | Service
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	2,931,000	3,283,000
North America (NA)
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	75,974,000	86,971,000
North America (NA) | Product
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	75,702,000	86,764,000
North America (NA) | Service
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	272,000	207,000
All Other
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	7,453,000	10,501,000
All Other | Product
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	6,178,000	9,322,000
All Other | Service
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	$ 1,275,000	$ 1,179,000
General Terms and Conditions
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Contract Type Sales Split	30.00%
Large National Customers
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Contract Type Sales Split	30.00%
Government Tenders
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Contract Type Sales Split	21.00%
Other Customers
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Contract Type Sales Split	19.00%

Equity Compensation (Narrative)

Equity Compensation (Narrative) (Details) $ / shares in Units, $ in Thousands		3 Months Ended
		Mar. 31, 2021USD ($)votes$ / sharesshares	Mar. 31, 2020USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.25
Share Based Compensation Arrangement By Share Based Payment Award Performance Period		3 years
Share-based Compensation Arrangement by Share-based Payment Award, Description		The 2018 Plan uses a fungible share-counting method, under which each Common Share underlying an award of stock options or stock appreciation rights ("SAR") will count against the number of total shares available under the 2018 Plan as one share; and each Common Share underlying any award other than a stock option or a SAR will count against the number of total shares available under the 2018 Plan as two shares. Shares underlying awards made under the 2003 Plan or 2013 Plan that are forfeited or remain unpurchased or undistributed upon termination or expiration of the awards will become available under the 2018 Plan for use in future awards. Any Common Shares that are added back to the 2018 Plan as the result of forfeiture, termination or expiration of an award granted under the 2018 Plan or the 2013 Plan will be added back in the same manner such shares were originally counted against the total number of shares available under the 2018 Plan or 2013 Plan, as applicable. Each Common Share that is added back to the 2018 Plan due to a forfeiture, termination or expiration of an award granted under the 2003 Plan will be added back as one Common Share.
Allocated Share-based Compensation Expense | $		$ 668	$ (380)
Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense | $		$ 1,580	1,200
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Net award activity (in shares)		2,671,108
Award requisite service period		3 years
Performance achievement level, lower range		0.00%
Performance achievement level, upper range		150.00%
Performance achievement level, target range		100.00%
Performance Shares | Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense | $		$ 668	$ 425
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	[1]	905,188
2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Share Awards Underlying from 2003 Plan		376,516
Weighted Average | Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period for recognition of unrecognized compensation costs		3 years
Class B Common Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Number of Votes | votes		10
Common Stock, Shares, Issued		3,667
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Holders Percentage of Total Outstanding		99.90%
[1]	*    Shares available for grant under the 2018 Plan as of March 31, 2021 reduced by net restricted stock and restricted stock unit and performance share and performance share unit award activity of 2,671,108 shares.

Equity Compensation Share-based

Equity Compensation Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	$ 668	$ (380)
Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	1,580	1,200
Restricted Stock and Restricted Stock Units (RSUs) | Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	912	775
Performance Shares | Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	$ 668	$ 425

Equity Compensation Unrecognize

Equity Compensation Unrecognized Compensation Expense (Details) $ in Thousands	Mar. 31, 2021USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 21,270
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	9,537
Restricted Stock and Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 11,733

Equity Compensation (Options Ac

Equity Compensation (Options Activity) (Details)	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options outstanding at beginning of period (in shares) | shares	1,081,804
Canceled (in shares) | shares	(38,200)
Options outstanding at end of period (in shares) | shares	1,043,604
Weighted Average Exercise Price
Options outstanding at beginning of period - Weighted Average Exercise Price (in dollars per share)	$ 16.07
Canceled - Weighted Average Exercise Price (in dollars per share)	17.01
Options outstanding at end of period - Weighted Average Exercise Price (in dollars per share)	$ 16.03
Options exercisable at end of period (in shares) | shares	1,043,604
Stock Options
Weighted Average Exercise Price
Options outstanding at end of period - Weighted Average Exercise Price (in dollars per share)	$ 16.03
Options available for grant at end of period (in shares) | shares	905,188	[1]
$12.15 – $20.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, lower limit (in dollars per share)	$ 12.15
$12.15 – $20.00 | Stock Options
Weighted Average Exercise Price
Options outstanding at end of period - Weighted Average Exercise Price (in dollars per share)	12.69
$30.01 – $33.36
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, upper limit (in dollars per share)	33.36
$30.01 – $33.36 | Stock Options
Weighted Average Exercise Price
Options outstanding at end of period - Weighted Average Exercise Price (in dollars per share)	$ 33.36
[1]	*    Shares available for grant under the 2018 Plan as of March 31, 2021 reduced by net restricted stock and restricted stock unit and performance share and performance share unit award activity of 2,671,108 shares.

Equity Compensation (Stock Opti

Equity Compensation (Stock Options Outstanding by Exercise Price) (Details) - $ / shares	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 16.03	$ 16.07
$12.15 – $20.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower limit (in dollars per share)	12.15
$12.15 – $20.00 | Minimum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, upper limit (in dollars per share)	12.15
$12.15 – $20.00 | Maximum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, upper limit (in dollars per share)	20
$20.01 – $30.00 | Minimum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, upper limit (in dollars per share)	20.01
$20.01 – $30.00 | Maximum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, upper limit (in dollars per share)	30
$30.01 – $33.36
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, upper limit (in dollars per share)	33.36
$30.01 – $33.36 | Minimum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, upper limit (in dollars per share)	30.01
$30.01 – $33.36 | Maximum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, upper limit (in dollars per share)	$ 33.36
Stock Options
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding - Number Outstanding at end of period (in shares)	1,043,604
Options Outstanding - Weighted Average Remaining Contractual Life	3 years 6 months
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 16.03
Options Exercisable - Number Exercisable At end of period (in shares)	1,043,604
Options Exercisable - Weighted Average Exercise Price (in dollars per share)	$ 16.03
Stock Options | $12.15 – $20.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding - Number Outstanding at end of period (in shares)	750,159
Options Outstanding - Weighted Average Remaining Contractual Life	4 years 8 months 12 days
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 12.69
Options Exercisable - Number Exercisable At end of period (in shares)	750,159
Options Exercisable - Weighted Average Exercise Price (in dollars per share)	$ 12.69
Stock Options | $20.01 – $30.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding - Number Outstanding at end of period (in shares)	288,949
Options Outstanding - Weighted Average Remaining Contractual Life	4 months 24 days
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 24.45
Options Exercisable - Number Exercisable At end of period (in shares)	288,949
Options Exercisable - Weighted Average Exercise Price (in dollars per share)	$ 24.45
Stock Options | $30.01 – $33.36
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding - Number Outstanding at end of period (in shares)	4,496
Options Outstanding - Weighted Average Remaining Contractual Life	1 month 6 days
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 33.36
Options Exercisable - Number Exercisable At end of period (in shares)	4,496
Options Exercisable - Weighted Average Exercise Price (in dollars per share)	$ 33.36

Equity Compensation Restricted

Equity Compensation Restricted Stock Activity (Details) - Restricted Stock and Restricted Stock Units (RSUs)	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance | shares	1,145,058
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | shares	617,707
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | shares	(8,190)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance | shares	1,754,575
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares	$ 8.62
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares	8.48
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value | $ / shares	9.38
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending Balance | $ / shares	$ 8.57

Equity Compensation Performance

Equity Compensation Performance Share Activity (Details) - Performance Shares - $ / shares	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	1,498,604	1,026,785
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	$ 8.53	$ 8.55
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	471,819
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 8.49

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) by Component (Changes in Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning Balance	$ 45,436	$ 3,128
OCI before reclassifications	4,929	(5,053)
Amount reclassified from accumulated OCI	305	548
Other Comprehensive Income (Loss)	5,234	(4,505)
Ending Balance	50,670	(1,377)
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning Balance	50,329	8,898
OCI before reclassifications	2,802	1,664
Amount reclassified from accumulated OCI	0	0
Other Comprehensive Income (Loss)	2,802	1,664
Ending Balance	53,131	10,562
Accumulated Long-Term Notes Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning Balance	(517)	(2,491)
OCI before reclassifications	2,875	(5,858)
Amount reclassified from accumulated OCI	0	0
Other Comprehensive Income (Loss)	2,875	(5,858)
Ending Balance	2,358	(8,349)
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning Balance	(3,674)	(3,299)
OCI before reclassifications	470	(598)
Amount reclassified from accumulated OCI	(121)	429
Other Comprehensive Income (Loss)	349	(169)
Ending Balance	(3,325)	(3,468)
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning Balance	(702)	20
OCI before reclassifications	(1,218)	(261)
Amount reclassified from accumulated OCI	426	119
Other Comprehensive Income (Loss)	(792)	(142)
Ending Balance	$ (1,494)	$ (122)

Accumulated Other Comprehensi_4

Accumulated Other Comprehensive Income (Loss) by Component (Reclassified Out of Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Cost of Products Sold	$ (141,564)	$ (155,452)
Amortization of prior service costs and unrecognized gains	(58,821)	(61,738)
Income tax provision	(1,870)	(2,100)
Net Sales	196,202	218,440
Accumulated Defined Benefit Plans Adjustment [Member] | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Amortization of prior service costs and unrecognized gains	(121)	429
Income tax provision	0	0
Net loss from Continuing Operations	(121)	429
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Income (Loss) from Continuing Operations before Income Taxes	474	150
Income tax provision	(48)	(31)
Net loss from Continuing Operations	426	119
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | Reclassification out of Accumulated Other Comprehensive Income | Foreign currency forward contracts
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Cost of Products Sold	452	35
Net Sales	$ 22	$ 115

Charges Related To Restructur_3

Charges Related To Restructuring Activities (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 6,253,000
Charges	1,552,000	$ 1,392,000
Payments	(6,283,000)	(1,870,000)
Ending Balance	1,522,000
Severance
Restructuring Reserve [Roll Forward]
Beginning Balance	6,249,000
Charges	1,276,000
Payments	(6,283,000)
Ending Balance	1,242,000
Contract Termination
Restructuring Reserve [Roll Forward]
Beginning Balance	4,000
Charges	276,000
Payments	0
Ending Balance	280,000
North America (NA)
Restructuring Reserve [Roll Forward]
Beginning Balance	179,000
Charges	822,000	691,000
Restructuring Reserve, Accrual Adjustment	822,000
Payments	(236,000)
Ending Balance	765,000
North America (NA) | Severance
Restructuring Reserve [Roll Forward]
Beginning Balance	179,000
Charges	822,000	691,000
Payments	(236,000)
Ending Balance	765,000
North America (NA) | Contract Termination
Restructuring Reserve [Roll Forward]
Beginning Balance	0
Restructuring Reserve, Accrual Adjustment	0
Payments	0
Ending Balance	0
Europe (EMEA)
Restructuring Reserve [Roll Forward]
Beginning Balance	5,908,000
Charges	730,000	665,000
Payments	(6,047,000)
Ending Balance	591,000
Europe (EMEA) | Severance
Restructuring Reserve [Roll Forward]
Beginning Balance	5,904,000
Charges	454,000	592,000
Payments	(6,047,000)
Ending Balance	311,000
Europe (EMEA) | Contract Termination
Restructuring Reserve [Roll Forward]
Beginning Balance	4,000
Charges	276,000	73,000
Payments	0
Ending Balance	280,000
All Other
Restructuring Reserve [Roll Forward]
Beginning Balance	166,000
Charges	0	36,000
Payments	0
Ending Balance	166,000
All Other | Severance
Restructuring Reserve [Roll Forward]
Beginning Balance	166,000
Charges	0	$ 36,000
Payments	0
Ending Balance	166,000
All Other | Contract Termination
Restructuring Reserve [Roll Forward]
Beginning Balance	0
Charges	0
Payments	0
Ending Balance	$ 0

Charges Related To Restructur_4

Charges Related To Restructuring Activities Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Restructuring Cost and Reserve [Line Items]
Charges	$ 1,552,000	$ 1,392,000
Restructuring and Related Activities, Expected Payout Period	24 months
Payments	$ (6,283,000)	(1,870,000)
Severance
Restructuring Cost and Reserve [Line Items]
Charges	1,276,000
Payments	(6,283,000)
Contract Termination
Restructuring Cost and Reserve [Line Items]
Charges	276,000
Payments	0
North America (NA)
Restructuring Cost and Reserve [Line Items]
Charges	822,000	691,000
Restructuring Reserve, Accrual Adjustment	822,000
Payments	(236,000)
North America (NA) | Severance
Restructuring Cost and Reserve [Line Items]
Charges	822,000	691,000
Payments	(236,000)
North America (NA) | Contract Termination
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	0
Payments	0
Europe (EMEA)
Restructuring Cost and Reserve [Line Items]
Charges	730,000	665,000
Payments	(6,047,000)
Europe (EMEA) | Severance
Restructuring Cost and Reserve [Line Items]
Charges	454,000	592,000
Payments	(6,047,000)
Europe (EMEA) | Contract Termination
Restructuring Cost and Reserve [Line Items]
Charges	276,000	73,000
Payments	0
All Other
Restructuring Cost and Reserve [Line Items]
Charges	0	36,000
Payments	0
All Other | Severance
Restructuring Cost and Reserve [Line Items]
Charges	0	$ 36,000
Payments	0
All Other | Contract Termination
Restructuring Cost and Reserve [Line Items]
Charges	0
Payments	$ 0

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Valuation Allowance [Line Items]
Reversal of Accrued Withholding Taxes on Earnings		$ 988,000
Effective income tax rate, continuing operations	(15.40%)	74.20%
U.S. statutory income tax rate	21.00%
Effective income tax rate, continuing operations	(15.40%)	74.20%
U.S. statutory income tax rate	21.00%

Net Earnings (Loss) Per Commo_3

Net Earnings (Loss) Per Common Share Computation of Basic and Diluted Net Earnings (Loss) Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Net Income (Loss) per Share—Basic
Average common shares outstanding		34,495	33,784
Net Loss		$ (14,044)	$ 732
Net earnings (loss) per common share		$ (0.41)	$ 0.02
Net Income (Loss) per Share—Assuming Dilution
Average common shares outstanding		34,495	33,784
Stock options and awards		715	69
Average common shares assuming dilution		35,210	33,853
Net Loss		$ (14,044)	$ 732
Net earnings (loss) per per common share—assuming dilution (in dollars per share)	[1]	$ (0.41)	$ 0.02
[1]	Net income (loss) per common share assuming dilution calculated utilizing weighted average shares outstanding-basic for the periods in which there was a net loss.

Net Earnings (Loss) Per Commo_4

Net Earnings (Loss) Per Common Share Textuals (Details) - Stock Options - $ / shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	1,100,648	2,366,261
Antidilutive share granted, average exercise price	$ 24.45	$ 24.45
Fair value stock price	$ 9.32	$ 7.75

Concentration Of Credit Risk (D

Concentration Of Credit Risk (Details)	Mar. 31, 2021USD ($)
Risks and Uncertainties [Abstract]
Retained Recourse Obligation For Events Of Default Under Contracts	$ 1,128,000
Events of Default Under Contract by Third Party	$ 8,951,000

Derivatives Notional Amounts -

Derivatives Notional Amounts - Designated as Hedges (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	$ 60,687	$ 54,750
Gain (Loss)	(987)	703
Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	96,967	124,228
Unrealized Gain (Loss)	(1,689)	(814)
USD / CHF | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	1,240	1,675
Unrealized Gain (Loss)	(1)	(11)
USD / EUR | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	44,156	56,187
Unrealized Gain (Loss)	(902)	(636)
USD / GBP | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	1,892	2,467
Unrealized Gain (Loss)	(97)	(19)
USD / SEK | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	2,009	2,658
Unrealized Gain (Loss)	(60)	(41)
USD / MXN | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	2,492	2,230
Unrealized Gain (Loss)	258	334
EUR / CHF | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	3,847	5,037
Unrealized Gain (Loss)	56	10
EUR / GBP | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	14,796	19,060
Unrealized Gain (Loss)	(488)	44
EUR / SEK | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	7,586	10,162
Unrealized Gain (Loss)	(96)	(73)
EUR / NOK | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	3,532	4,167
Unrealized Gain (Loss)	(116)	(64)
AUD / NZD | Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	6,497	6,579
Gain (Loss)	(46)	(35)
AUD / NZD | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	614	781
Unrealized Gain (Loss)	(18)	(13)
DKK / SEK | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	2,273	3,329
Unrealized Gain (Loss)	17	9
NOK / SEK | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	2,461	3,431
Unrealized Gain (Loss)	(66)	(50)
AUD / THB | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	3,888	4,963
Unrealized Gain (Loss)	(260)	(221)
NZD / THB | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	1,381	1,755
Unrealized Gain (Loss)	(55)	(55)
USD / THB | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	3,114	4,152
Unrealized Gain (Loss)	89	(56)
EUR / THB | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	1,034	1,332
Unrealized Gain (Loss)	12	18
GBP / THB | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	652	842
Unrealized Gain (Loss)	$ 38	$ 10

Derivatives Notional Amounts _2

Derivatives Notional Amounts - Not Designated as Hedges (Details) - Not Designated as Hedging Instrument [Member] - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Derivative [Line Items]
Notional Amount	$ 60,687		$ 54,750
Gain (Loss)	(987)		703
Forward exchange contracts—net
Derivative [Line Items]
Gain (Loss)		$ (724)
AUD / USD
Derivative [Line Items]
Notional Amount	5,776		6,046
Gain (Loss)	111		(159)
CAD / USD
Derivative [Line Items]
Notional Amount	13,086		8,320
Gain (Loss)	(139)		88
DKK / USD
Derivative [Line Items]
Notional Amount	8,859		8,690
Gain (Loss)	(320)		207
GBP / USD
Derivative [Line Items]
Notional Amount	16,947		16,062
Gain (Loss)	(418)		338
NOK / USD
Derivative [Line Items]
Notional Amount	9,522		9,053
Gain (Loss)	(175)		264
AUD / NZD
Derivative [Line Items]
Notional Amount	6,497		6,579
Gain (Loss)	$ (46)		$ (35)

Derivatives Balance Sheet Locat

Derivatives Balance Sheet Location (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Other Current Assets
Derivatives, Fair Value [Line Items]
Derivative assets	$ 723	$ 1,321
Other Current Assets | Foreign currency forward contracts | Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivative assets	470	424
Other Current Assets | Foreign currency forward contracts | Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivative assets	253	897
Accrued Expenses
Derivatives, Fair Value [Line Items]
Derivative liabilities	3,399	1,432
Accrued Expenses | Foreign currency forward contracts | Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivative liabilities	2,159	1,238
Accrued Expenses | Foreign currency forward contracts | Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivative liabilities	$ 1,240	$ 194

Derivatives Gain (Loss) in Stat

Derivatives Gain (Loss) in Statement of Finacial Position (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Derivative Instruments, Gain (Loss) [Line Items]
Current period loss on cash flow hedges	$ (875,000)	$ (142,000)
Cash Flow Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss)	474,000	150,000
Foreign currency forward contracts | Cash Flow Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Current period loss on cash flow hedges	(1,218,000)	(261,000)
Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	(426,000)	(119,000)
Amount of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion and Amount Excluded from Effectiveness Testing)	0	64,000
Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss)	$ (987,000)		$ 703,000
Not Designated as Hedging Instrument [Member] | Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss)		$ (724,000)

Derivatives Narrative (Details)

Derivatives Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Jun. 30, 2017	Mar. 31, 2016	Dec. 31, 2020	Dec. 31, 2017
Derivative [Line Items]
Proceeds from Issuance of Warrants				$ 12,376,000
Foreign currency forward contracts
Derivative [Line Items]
Notional amount of derivatives, matured during period	$ 26,667,000	$ 42,894,000
Selling, General and Administrative Expenses | Foreign currency forward contracts
Derivative [Line Items]
Loss on derivative	$ (987,000)	(724,000)
Minimum
Derivative [Line Items]
Derivative, percentage of forcasted transactions with currency rate exposure	50.00%
Maximum
Derivative [Line Items]
Derivative, percentage of forcasted transactions with currency rate exposure	90.00%
Cash Flow Hedging [Member]
Derivative [Line Items]
Gain (Loss)	$ (474,000)	(150,000)
Cash Flow Hedging [Member] | Sales [Member]
Derivative [Line Items]
Gain recognized in income	22,000
Loss on derivative		(115,000)
Cash Flow Hedging [Member] | Cost of Sales [Member]
Derivative [Line Items]
Loss on derivative	(452,000)	$ (35,000)
Convertible Subordinated Debt | Convertible Senior Notes at 5.00% February 2021
Derivative [Line Items]
Debt Instrument, Face Amount	$ 0			$ 150,000,000	$ 1,250,000
Interest rate (as a percent)	5.00%
Convertible Subordinated Debt | Convertible Senior Notes at 4.50% February 2022 [Domain]
Derivative [Line Items]
Proceeds from Issuance of Warrants			$ 14,100,000
Convertible due 2022 - Bond Hedge, Fair Value at Issuance						$ 24,780,000
Debt Instrument, Face Amount	$ 2,650,000		$ 120,000,000		$ 81,500,000
Interest rate (as a percent)	4.50%

Derivatives Fair Value of Conve

Derivatives Fair Value of Convertible Debt Hedges (Details)	12 Months Ended
	Dec. 31, 2019USD ($)
Convertible Subordinated Debt | Convertible Senior Notes at 4.50% February 2022 [Domain]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Convertible Debt Conversion Feature Gain (Loss)	$ (6,193,000)

Fair Values (Assets and Liabili

Fair Values (Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details) - Forward exchange contracts—net - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities), at fair value, net	$ 0	$ 0
Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities), at fair value, net	(2,676)	(111)
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities), at fair value, net	$ 0	$ 0

Fair Values (Details of Book Va

Fair Values (Details of Book Value and Fair Value of Financial Instruments) (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents	$ 86,052	$ 105,298	$ 98,932	$ 80,063
Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents	86,052	105,298
Other investments	84	85
Installment receivables, net of reserves	1,145	1,322
Debt Instrument, Fair Value Disclosure	(288,590)	(245,053)
Carrying Value | Convertible Senior Notes at 5.00% February 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	0	(1,242)
Carrying Value | Convertible Senior Notes at 4.50% February 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(2,627)	(73,869)
Carrying Value | Convertible Senior Notes at 5.00% November 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(71,939)	(62,984)
Carrying Value | Series II Convertible Senior Notes at 5.00% November 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(75,334)	(64,919)
Carrying Value | Other Notes and Capital Lease Obligations
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(20,904)	(42,039)
Carrying Value | Convertible Senior Notes at 4.25% March 2026
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(117,786)	0
Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents	86,052	105,298
Other investments	84	85
Installment receivables, net of reserves	1,145	1,322
Debt Instrument, Fair Value Disclosure	(287,592)	(237,948)
Fair Value | Convertible Senior Notes at 5.00% February 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	0	(1,264)
Fair Value | Convertible Senior Notes at 4.50% February 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(2,480)	(70,633)
Fair Value | Convertible Senior Notes at 5.00% November 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(70,377)	(60,035)
Fair Value | Series II Convertible Senior Notes at 5.00% November 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(75,510)	(64,090)
Fair Value | Other Notes and Capital Lease Obligations
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(20,351)	(41,926)
Fair Value | Convertible Senior Notes at 4.25% March 2026
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(118,874)	0
Foreign currency forward contracts | Other Current Assets | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative assets	723	1,321
Foreign currency forward contracts | Other Current Assets | Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative assets	723	1,321
Foreign currency forward contracts | Accrued Expenses | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liabilities	(3,399)	(1,432)
Foreign currency forward contracts | Accrued Expenses | Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liabilities	(3,399)	(1,432)
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 1 [Member] | Foreign currency forward contracts
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative assets (liabilities), at fair value, net	0	0
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 2 | Foreign currency forward contracts
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative assets (liabilities), at fair value, net	(2,676)	(111)
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3 [Member] | Foreign currency forward contracts
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative assets (liabilities), at fair value, net	$ 0	$ 0

Business Segments (Information

Business Segments (Information by Segment) (Details) - USD ($)	3 Months Ended			12 Months Ended
	Mar. 31, 2021	Sep. 30, 2020	Mar. 31, 2020	Dec. 31, 2020
Segment Reporting Information [Line Items]
Net Sales	$ 196,202,000		$ 218,440,000
Restructuring Reserve	1,522,000			$ 6,253,000
Charges	(1,552,000)		(1,392,000)
Gain on sale of business	0		9,590,000	(9,790,000)
Operating Income (Loss)	(5,735,000)		9,448,000
Interest Revenue (Expense), Net	(5,730,000)		(6,616,000)
Earnings (loss) before income taxes	(12,174,000)		2,832,000
Loss on debt extinguishment including debt finance charges and fees	(709,000)	$ 761,000	0
Europe (EMEA)
Segment Reporting Information [Line Items]
Net Sales	112,775,000		120,968,000
Restructuring Reserve	591,000			5,908,000
Charges	(730,000)		(665,000)
Operating Income (Loss)	3,832,000		6,850,000
North America (NA)
Segment Reporting Information [Line Items]
Net Sales	75,974,000		86,971,000
Restructuring Reserve	765,000			179,000
Restructuring Reserve, Accrual Adjustment	822,000
Charges	(822,000)		(691,000)
Operating Income (Loss)	(2,375,000)		(2,045,000)
All Other
Segment Reporting Information [Line Items]
Net Sales	7,453,000		10,501,000
Restructuring Reserve	166,000			166,000
Charges	0		(36,000)
Operating Income (Loss)	(5,640,000)		(3,555,000)
Operating Segments [Member] | Europe (EMEA)
Segment Reporting Information [Line Items]
Net Sales	112,775,000		120,968,000
Operating Segments [Member] | North America (NA)
Segment Reporting Information [Line Items]
Net Sales	75,974,000		86,971,000
Operating Segments [Member] | All Other
Segment Reporting Information [Line Items]
Net Sales	7,453,000		10,501,000
Intersegment revenues
Segment Reporting Information [Line Items]
Net Sales	19,503,000		27,237,000
Intersegment revenues | Europe (EMEA)
Segment Reporting Information [Line Items]
Net Sales	5,308,000		4,226,000
Intersegment revenues | North America (NA)
Segment Reporting Information [Line Items]
Net Sales	14,195,000		20,482,000
Intersegment revenues | All Other
Segment Reporting Information [Line Items]
Net Sales	0		2,529,000
Severance
Segment Reporting Information [Line Items]
Restructuring Reserve	1,242,000			6,249,000
Charges	(1,276,000)
Severance | Europe (EMEA)
Segment Reporting Information [Line Items]
Restructuring Reserve	311,000			5,904,000
Charges	(454,000)		(592,000)
Severance | North America (NA)
Segment Reporting Information [Line Items]
Restructuring Reserve	765,000			179,000
Charges	(822,000)		(691,000)
Severance | All Other
Segment Reporting Information [Line Items]
Restructuring Reserve	166,000			166,000
Charges	0		(36,000)
Contract Termination
Segment Reporting Information [Line Items]
Restructuring Reserve	280,000			4,000
Charges	(276,000)
Contract Termination | Europe (EMEA)
Segment Reporting Information [Line Items]
Restructuring Reserve	280,000			4,000
Charges	(276,000)		(73,000)
Contract Termination | North America (NA)
Segment Reporting Information [Line Items]
Restructuring Reserve	0			0
Restructuring Reserve, Accrual Adjustment	0
Contract Termination | All Other
Segment Reporting Information [Line Items]
Restructuring Reserve	0			$ 0
Charges	0
Lifestyle Products [Domain] | Operating Segments [Member] | Europe (EMEA)
Segment Reporting Information [Line Items]
Net Sales	58,298,000		58,303,000
Lifestyle Products [Domain] | Operating Segments [Member] | North America (NA)
Segment Reporting Information [Line Items]
Net Sales	36,185,000		42,541,000
Lifestyle Products [Domain] | Operating Segments [Member] | All Other
Segment Reporting Information [Line Items]
Net Sales	2,524,000		3,132,000
Mobility and Seating [Domain] | Operating Segments [Member] | Europe (EMEA)
Segment Reporting Information [Line Items]
Net Sales	44,222,000		52,778,000
Mobility and Seating [Domain] | Operating Segments [Member] | North America (NA)
Segment Reporting Information [Line Items]
Net Sales	22,733,000		29,574,000
Mobility and Seating [Domain] | Operating Segments [Member] | All Other
Segment Reporting Information [Line Items]
Net Sales	3,218,000		5,435,000
Respiratory Therapy [Domain] | Operating Segments [Member] | Europe (EMEA)
Segment Reporting Information [Line Items]
Net Sales	6,038,000		4,931,000
Respiratory Therapy [Domain] | Operating Segments [Member] | North America (NA)
Segment Reporting Information [Line Items]
Net Sales	16,784,000		14,649,000
Respiratory Therapy [Domain] | Operating Segments [Member] | All Other
Segment Reporting Information [Line Items]
Net Sales	282,000		533,000
Other [Domain] | Operating Segments [Member] | Europe (EMEA)
Segment Reporting Information [Line Items]
Net Sales	4,217,000		4,956,000
Other [Domain] | Operating Segments [Member] | North America (NA)
Segment Reporting Information [Line Items]
Net Sales	272,000		207,000
Other [Domain] | Operating Segments [Member] | All Other
Segment Reporting Information [Line Items]
Net Sales	$ 1,429,000		$ 1,401,000